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Preface
 
Hereditary tyrosinamemia type I (HT1) is an inborn error of metabolism. It is caused 
by an enzyme deficiency in the tyrosine catabolism pathway and leads to 
accumulation of the metabolite fumarylacetoacetate (FAA). In humans FAA is 
naturally produced in very small amounts in the liver and kidneys throughout life, 
apparently with no negative consequences. However the accumulation of FAA in HT1 
has striking pathological and life threatening effects including an extreme risk of 
cancer development (hepatocellular carcinoma). A mysterious mosaic pattern of 
hepatocytes, probably the result of a high local mutation frequency, was revealed in 
1994 in a large majority of the HT1 patients.  Evidence therefore points to HT1 being 
strongly associated with DNA instability. 
 
The devastating effect of HT1 metabolites is the starting point for this thesis. We 
have described DNA alterations in Norwegian HT1 patients, and investigated the 
possible role of DNA repair systems in the pathogenesis of HT1.  
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Abbreviations and nomenclature 
Aag  alkyladenine DNA glycosylase 
Ala-DH aminolevulinic acid dehydratase 
AT   ataxia telangiectasia  
BER  base excision repair  
BS  Bloom syndrome 
DR  direct repair  
FAA  fumarylacetoacetate 
Fah  fumarylacetoacetate hydrolase, fumarylacetoacetase 
GC-MS gas chromatography–mass spectrometry  
GGR  global genome repair  
HGMD Human Gene Mutation Database  
HR  homologous recombination  
HT1  hereditary tyrosinaemia type I 
4HPPD 4-hydroxy phenylpuruvate dioxygenase 
MAA  maleylacetoacetate 
Mbd4  methyl binding domain protein 4 
MMR  mismatch repair 
MS  mass spectrometry 
Mth1  MutT homolog 1 (8-oxodGTPase) 
Myh  MutY homolog DNA glycosylase 
Neil1  endonuclease-eight-like DNA glycosylase 1 
Neil2  endonuclease-eight-like DNA glycosylase 2 
Neil3  endonuclease-eight-like DNA glycosylase 3  
NHEJ  non homologous end joining  
NIR  nucleotide incision repair 
NTBC  2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione 
Nth1  endonuclease three like DNA glycosylase 1 
Ogg1  8-oxoguanine DNA glycosylase1 
ROS  reactive oxygen species 
SA  succinylacetone 
Smug  single-strand selective monofunctional uracil-DNA glycosylase 
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TAT  tyrosine aminotransferase  
Tdg  thymine-DNA glycosylase
TCR  transcription-coupled repair  
Udg  uracil-DNA glycosylase
Ung  uracil-N glycosylase
XP  xeroderma pigmentosum 
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 Introduction
Important years in the history of tyrosinaemia type I 
 
1849  The amino acid tyrosine was purified for the first time (Bopp 1849) 
1908  Inborn errors of metabolism were established as a specific group of diseases 
(Garrod) (Scriver 2008) 
1955 The most important enzymes involved in tyrosine degradation were described 
for the first time. (Knox 1955) 
1956 A probable tyrosinaemia type I patient was described for the first time. 
(BABER 1956) 
1977   Succinylacetone was demonstrated in urine from patients with 
hypertyrosiaemia, and Fah deficiency was deduced as the primary enzyme 
defect (Lindblad, Lindstedt, and Steen 1977) 
1979   Fah deficiency was demonstrated in liver tissue from patients with 
hypertyrosinaemia (Fallstrøm et al. 1979) 
1992 The drug NTBC was introduced into the treatment. (Lindstedt et al. 1992) 
1994 The phenomenon of self-induced correction was described. 
 (Kvittingen et al. 1994) 
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Metabolism of tyrosine 
Tyrosine  
The amino acid tyrosine exists principally as either L-tyrosine or R-tyrosine. L-
tyrosine is the only metabolically active form in mammals, thus the term “tyrosine” is 
used interchangeably with L-tyrosine. The molecular weight of tyrosine is 181.2 
g/mol. The solubility is 2.5mM at 25°C in water which makes it one of the least 
soluble amino acids in cells and body fluids. In humans free tyrosine is classified as a 
semi essential amino acid with two sources: either hydrolysis of proteins from the diet 
and body tissues, or hydroxylation of the essential amino acid phenylalanine. 
Tyrosine is the starting point for the synthesis of several important substances like 
catecholamines, thyroid hormones and melanin pigments. Most of the free tyrosine is 
however, incorporated into proteins or broken down to fumarate and acetoacetate. 
Tyrosine is thus both a glucogenic and a ketogenic amino acid. (Mitchell et al. 2001) 
The reference values for tyrosine levels in body fluids from our laboratory 
(Department of Medical Biochemistry, Oslo University Hospital) are given in Table 1:  
 
Table 1: Normal levels of tyrosine in humans 
 Age Normal Range 
Plasma (μM) < 1 month 30 – 120 
 1 month – 6 year 30 – 110 
 > 6 years 30 – 100 
Cerebrospinal fluid (μM) Adult 4 – 12 
Urine (μmol/mmol creatinine) < 1 month 6 – 70 
 1 month – 1 year 15 – 90 
 1 – 6 years 8 – 65 
 > 6 years 3 – 40 
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The degradation of tyrosine 
 
 
 
 
 
 
 
 
 
 
Figure 1 Tyrosine degradation and Fah deficiency. The steps are described in detail 
in the text below. 
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The complete degradation of tyrosine (Figure 1) takes place in the cytosol primarily of 
hepatocytes and to some extent in renal tubular cells (Greenbeg D.M. 1969;LIN and 
Knox 1958). 
Step 1: The formation of p-OH-phenylpyruvate from tyrosine by the enzyme 
tyrosine amino transferase (TAT) is the rate-limiting step of this 
catabolic pathway (Coufalik and Monder 1980;Dickson, Marston, and 
Pogson 1981;Ohisalo, Laskowska-Klita, and Andersson 1982). 
Step 2:  Homogentisic acid is formed from p-OH-phenylpyruvate through a 
complex series of reactions which involve decarboxylation, oxidation 
and migration of the side chain on the benzene ring. The reactions are 
catalysed by the enzyme 4HPPD. This enzyme is dependent on Cu and 
vitamin C, and is in humans exclusively expressed in the parenchymal 
cells of liver and kidney. (Fellman, Fujita, and Roth 1972) The enzyme 
is inhibited by the metabolite fumarylacetoacetate (FAA), which explains 
why tyrosine and p-OH-phenyllactate accumulate in the body fluids of 
HT1-patients. The enzyme is also the target for the enzyme inhibitor 
NTBC that is used in treatment of HT1.   
Step 3:  Homogentisic acid is oxidatively cleaved to maleylacetoacetate (MAA) 
by homogentisate dioxygenase. The enzyme contains reactive 
sulfhydryl groups and requires Fe++ (mercaptides). 
Step 4:  MAA is isomerized to FAA by maleylacetoacetate isomerase. This 
enzyme requires reduced glutathione probably in order to maintain its 
sulfhydryl groups in reduced form. 
Step 5:  FAA is cleaved by fumarylacetoacetate hydrolase 
(fumarylacetoacetase) (Fah) to yield fumarate and acetoacetate. In Fah 
deficiency FAA and probably MAA accumulate and are then reduced to 
succinylacetoacetate and further decarboxylated to succinylacetone 
(SA). SA is a potent inhibitor of -aminolevulinic acid–dehydratase in 
the hemesynthesis, and accumulation of SA leads to accumulation of -
aminolevulinic acid and possible porphyria like neurological crises. 
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Fumarylacetoacetate hydrolase 
Fumarylacetoacetate hydrolase (fumarylacetoacetase) (Fah) (E.C.3.7.1.2) is a 
hydrolase with no cofactors. It is a soluble, cytosolic homodimer with a molecular 
weight of 46,3 kDa per subunit. Fah has been purified from rat, bovine and human 
liver (Berger et al. 1987;Mahuran et al. 1977;Van, van, I, and Berger 1990), and 
polyclonal antibodies have been developed (Berger et al. 1987). The structure of 
murine Fah is experimentally determined (Bateman et al. 2001) There is no solved 
structure for the human protein, but there is a high degree of homology between the 
murine and the human protein. 372 of 419 amino acids (89 %) are identical (paper I). 
Human Fah is mainly expressed in liver and renal tubular cells, is active over a wide 
pH range and has a Km of 1,3 μM FAA. (Kvittingen, Jellum, and Stokke 1981) In 
other tissues the activity is 2 - 5 % of the level in liver (Kvittingen, Halvorsen, and 
Jellum 1983).  
Hypertyrosinaemia in general 
Non-genetic conditions
Hypertyrosinaemia is seen subsequently to severe hepatocellular dysfunction 
(Fujinami et al. 1990;Iber et al. 1957) probably due to secondary inhibition of the first 
steps of tyrosine degradation. Transient hypertyrosinaemia of newborns is a common 
condition with uncertain clinical consequences (Scriver and Rosenberg 1973). The 
cause is probably immaturity of 4HPPD. Increased dietary protein load in the 
newborn period and a relative ascorbate deficiency are also possible explanations for 
the temporarily increased tyrosine levels (Mitchell et al. 2001). 
Genetic diseases 
Hepatorenal tyrosinaemia (tyrosinaemia type I) is caused by deficiency of Fah, the 
last enzyme of tyrosine degradation, and is the subject of this thesis.  
Oculocutaneous tyrosinaemia (tyrosinaemia type II) is caused by TAT 
deficiency, the first enzyme in tyrosine degradation, and is characterized by strongly 
elevated plasma tyrosine levels. Palmoplantar keratosis and painful corneal erosions 
are typical symptoms and respond to a protein restricted diet. Approximately 50 % of 
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patients develop mental retardation that cannot be reversed by dietary control. The 
mechanisms behind the neurological impairments are not fully understood. 
Primary 4HPPD deficiency (tyrosinaemia type III): A few patients with 
neurological symptoms but no symptoms from liver and kidneys have been described 
with this deficiency.  
Epidemiology 
Tyrosinaemia type I is a rare disease that occurs worldwide with varying frequency. 
The highest incidence is found in the province of Quebec in Canada, especially in the 
Saguenay-Lac St. Jean region, due to a complex founder effect. The carrier 
frequency in this area is about 1:20, with one patient per 1846 living births (prior to 
prenatal diagnosis) (De Braekeleer and Larochelle 1990;Grompe et al. 1995;Laberge 
1969). The incidence in the entire Quebec province is one patient per 16786 living 
births. In the rest of the world, including Scandinavia, the incidence before our 
studies had been estimated to be 1: 100,000 – 120,000 (Halvorsen 1980). Recently a 
higher incidence than average was proclaimed in one study from the Middle East but 
no number was given (Imtiaz et al. 2011). 
Genetics
The Fah gene consists of approximately 3,5 kb and is located on chromosome 15 
q23-25. The gene contains 14 exons.  The open reading frame consists of 1257 
nucleotides coding for 419 amino acids. HT1 is an autosomal recessive disease. 
Prior to this work at least 68 disease causing mutations had been described. 55 of 
them are registered in the HGMD database, (Stenson et al (2009) 2011) At least two 
previously described splicing mutations (Q64H G192>T (Rootwelt et al. 1994), and 
Q279R, A836>G (Kim et al. 2000) (Dreumont et al. 2001)) are not registered in the 
database. 11 disease causing mutations (9 missense/nonsense, 1 splicing, 1 small 
deletion) have recently been reported (Imtiaz et al. 2011). This gives the following 
distribution of mutation types: 44 missense/nonsense, 18 splicing, 4 small deletions, 
2 gross deletions, 1 small indel. The most common mutation worldwide is the splicing 
mutation IVS12+5g>a. Other mutations are typically found in certain areas, like 
G337S in Scandinavia, W262X in Finland and D233V in Turkey. Prior to this work 6 
disease causing mutations had been described in Norwegian patients. 
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Pathophysiology 
Severe hepatitis 
HT1 may be considered as a chemical hepatitis. The accumulation of toxic 
substances leads to cell destruction and compensatory accelerated regeneration of 
hepatocytes. The inflammation ultimately causes liver cirrhosis, and the reduction in 
functional liver parenchyma leads to liver failure. Development of hepatocellular 
carcinoma is common. Enzyme deficiencies upstream of Fah in the tyrosine 
degradation process do not affect the liver or the kidneys, thus apoptosis, necrosis, 
cirrhosis and cancer development are attributed to Fah deficiency and the specific 
HT1 metabolites FAA, MAA and SA  (Grompe 2001;Mitchell et al. 2001).  
Apoptosis
The flux through the tyrosine degradation pathway, and thus the toxic effect of the 
accumulating metabolites, can be regulated in Fah deficient mice with the drug 
NTBC. Endo and coworkers have shown that apoptosis occurs when NTBC 
treatment is terminated (Endo et al. 1997). The same mouse model was used by 
Kubo and coworkers to show that FAA triggers the caspase cascade in hepatocytes 
(leading to apoptotic proteolysis and cell death), and that caspase inhibitors reduce 
hepatocyte damage in Fah deficient mice (Kubo et al. 1998). In other studies renal 
tubular cells became apoptotic in Fah deficient mice when NTBC treatment was 
abolished. (Sun et al. 2000) (Endo and Sun 2002)  
Regenerating nodules and carcinoma  
Hepatocellular carcinomas occur very frequently in untreated HT1 patients. The 
mechanism behind the cancer development is not fully understood. FAA, but not SA 
and MAA, is mutagenic in vitro and increases oxidative damage by disrupting the 
sulfhydryl metabolism and by glutathione depletion (Jorquera and Tanguay 1997). 
FAA and MAA are alkylating agents and may alkylate functional groups of many 
cellular proteins like thiols and amines. The alkylating potential is due to the 
molecular structure (,-unsaturated carbonyl compound) of FAA and MAA. This 
means that these compounds may act as Michael acceptors in the Michael addition 
reaction. DNA damage caused by uncontrolled alkylation may be cytotoxic and/or 
mutagenic. Disrupted mitosis may lead to cell death, and disrupted base pairing 
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during replication may result in a permanently altered nucleotide sequence. Alkylation 
may furthermore trigger apoptosis, as recently reported (Lim et al. 2012) Inhibition of 
apoptotic signals may contribute to development of hepatocellular carcinoma in HT1 
patients. Increased resistance to cell death has been demonstrated in hepatocytes of 
fah-/- mice, induced by chronic liver disease (Vogel et al. 2004) and by activation of 
specific cell survival pathways (Orejuela et al. 2008). SA react with free and protein 
bound amino acids to form adducts (Manabe, Sassa, and Kappas 1985) (Prieto-
Alamo and Laval 1998).  
 Renal tumour development in HT1 has not been reported despite of 
catabolism of tyorisne renal tubuli cells (Fellman, Fujita, and Roth 1972;Greenbeg 
D.M. 1969;Lin and Knox 1958). This is a bit surprising because the risk of cancer 
development is so high in hepatocytes in HT1. The reason is not fully understood, but 
a lower rate of tyrosine catabolism and a lower replication rate in renal tubuli cells are 
probably parts of the explanation.      
Hypertyrosinaemia  
Blood tyrosine is elevated in HT1 patients because of a secondary inhibition of 
4HPPD activity. Although the hepatorenal symptoms are not attributed to tyrosine 
elevation, neurological development might be affected. Neurological symptoms are 
associated with both hypertyrosinaemia type I, II and III, and studies on animal 
models suggest that affected energy metabolism (inhibition of creatine kinase 
activity) and increased oxidative stress (decreased glutathione concentration) may be 
two possible mechanisms (de Andrade et al. 2011) (Sgaravatti et al. 2009). 
Other pathological changes  
Since SA is a potent inhibitor of the porphyrin synthetic enzyme Ala-DH (Figure 1), 
porphyria-like neurological crises may occur in untreated HT1 patients. In addition, 
SA is shown to have an immunosuppressive effect that might also contribute to the 
liver damage seen in HT1 (Tschudy et al. 1982).  
The cell autonomous model  
The metabolites immediately upstream of Fah (FAA and MAA) are not detectable in 
plasma and urine. This is probably because they react very rapidly by forming 
adducts with other molecules, or because they are transformed into 
17
succinylacetoacetate and SA. The direct damage caused by FAA and MAA is 
therefore likely to be limited to the cells in which they are formed. In contrast, SA is 
transported out of the cells and may affect other tissues as well. Consequently, the 
renal Fanconi syndrome in HT1 patients is assumed to be caused by circulating SA 
(Spencer et al. 1988;Spencer and Roth 1987). 
Clinical presentation
HT1 is characterised by clinical heterogeneity. The disease may present from infancy 
to adulthood and can be categorized as acute, subacute or chronic (Chakrapani A, 
Gissen, and McKiernan 2011;van Spronsen et al. 1994). The acute form presents 
before 6 months of age with symptoms of acute liver failure. The subacute form 
presents between 6 and 12 months of age with hepatosplenomegaly, failure to thrive, 
coagulopathy, rickets and hypotonia. The chronic form presents after 12 months of 
age, typically with chronic liver disease, hypophosphatemic rickets and/or porphyria-
like neurological crises.  
Liver disease 
The accumulating toxic metabolites in HT1 lead to liver failure, cirrhosis and/or 
hepatocellular carcinoma. The most severe form presents a few weeks after birth 
with dramatic symptoms of acute liver failure like oedema, ascites and bleeding 
diathesis due to hypoproteinemia. Additionally, non-specific symptoms like vomiting, 
diarrhoea and hypoglycaemia may be present. Sepsis is common. Severely reduced 
protein synthesis is a striking finding in HT1. The hepatic excretory functions are not 
however correspondingly affected. Jaundice is a late sign indicating that the liver may 
be so damaged that transplantation must be considered despite NTBC treatment.  
The chronic form of HT1 leads to liver cirrhosis which in most cases is 
described as a mixed micromacronodular type with a variable degree of steatosis 
(Dehner et al. 1989). Hepatocyte dysplasia is common, and the risk of malignant 
development is considerable. When the patient presents the first symptoms of HT1, 
cirrhosis or hepatocellular carcinoma may already be present.  
Renal dysfunction  
Hypophosphatemic rickets is common as a first symptom of the chronic form of HT1 
due to dysfunction of the proximal renal tubuli. Nephromegaly may be present at time 
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of diagnosis (Paradis et al. 1990), and some patients present with Fanconi syndrome: 
generalised aminoaciduria, glycosuria and renal tubular acidosis. Renal failure has 
also been reported (Santra et al. 2008).  
 
Neurological crises
Acute porphyria-like neurological crises may occur at any age in patients who are not 
being treated with NTBC due to the inhibition of heme synthesis by SA (Figure 1).  
The crises may in severe cases lead to respiratory paralysis and death (Mitchell et al. 
1990). 
Cardiomyopathy  
Hypertrophic cardiomyopathy has been described as common but usually benign in 
HT1 patients (Arora et al. 2006). However, in one infant myopathy was reported as 
the cause of death (Lindblad et al. 1987).
Pancreatic dysfunction 
Hypertrophy of the endocrine cells of the pancreas has been found in infants with 
HT1. The symptoms are that of hyperinsulinism with episodes of hypoglycaemia 
(Baumann et al. 2005).  
Diagnosis
HT1 is diagnosed by demonstrating presence of the pathognomonic metabolite SA 
and/or its precursors in urine (GC-MS). If only small amounts of SA are found, 
mutational analysis of blood samples should be performed. The demonstration of two 
known disease causing mutations confirms the diagnosis. Determination of Fah 
activity in lymphocytes, fibroblasts or liver tissue is not recommended as the only 
diagnostic measure when HT1 is suspected. The results of such assays must be 
interpreted with caution. Normal Fah activity in a liver biopsy may be due to sampling 
from a revertant nodule in a liver that otherwise lacks functionally active Fah. On the 
other hand, a false negative result may be caused by the pseudodeficiency gene 
(Rootwelt, Brodtkorb, and Kvittingen 1994) yielding low, but functionally sufficient, 
activity in all tissues.  
Standard biochemical analyses reflect the affected hepatic protein synthesis 
with elevated INR and reduced albumin. Coagulopathy is an important sign and may 
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be present without other signs of liver disease. ALAT, GT and bilirubin may be 
normal or slightly elevated. -fetoprotein is often grossly elevated at the time of 
diagnosis in acute HT1, but may be normal in chronic HT1. Urinary excretion of -
ALA may be increased. Analysis of amino acids in plasma shows elevated tyrosine, 
phenylalanine and methionine, but to varying degrees (Kvittingen and Holme 
2000;Mitchell et al. 2001). 
Newborn screening for HT1 has been performed since 1969 in the province of 
Quebec initially by measuring tyrosine levels in dried blood spots. In 1974 
measurement of blood -fetoprotein was added. Since 1980 newborn screening for 
HT1 in the province of Ouebec is done by measurement of SA in urine (Scriver 
2006). SA is well suited as a newborn screening marker, giving low rates of both 
false positive and false negative results. SA has virtually eliminated the problems with 
false positive diagnoses in Quebec (Scriver 2006). The most common screening 
method today is  MS-MS blood spot analysis of SA (Allard et al. 2004) 
Treatment
Prior to 1992, a tyrosine- and phenylalanine restricted diet and liver transplantation 
were the only available treatment options for HT1. Since the drug NTBC (2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione) (nitisinone, OrfadinTM) became available 
in 1992,  the prognosis of HT1 has dramatically improved (Holme and Lindstedt 
2000). NTBC is a potent inhibitor of the enzyme 4HPPD, which is upstream of Fah in 
the tyrosine degradation pathway. Blocking this enzyme prevents production of the 
toxic metabolites FAA, MAA and SA (Holme and Lindstedt 1998;Lindstedt et al. 
1992). 
Tyrosine and phenylalanine restriction is necessary to prevent excessive 
levels of plasma tyrosine that might otherwise lead to acute corneal erosions and 
possibly cause neurological deffects over time. In addition to a low protein diet, 
patients are given a protein hydrolysate of amino acids free of tyrosine and 
phenylalanine to secure a sufficient supply of other amino acids (Mitchell et al. 2001). 
Liver transplantation must be performed in cases where the patient does not 
respond to NTBC or develops hepatocellular carcinoma in spite of adequate NTBC 
treatment (Holme and Lindstedt 2000).
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The Norwegian patients 
During the last three decades 30 patients (11 girls 19 boys) have been diagnosed 
with HT1 in our laboratory at the Department of Medical Biochemistry, Oslo 
University Hospital (Figure 2), the only laboratory for diagnosis of inborn errors of 
metabolism in Norway. 
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Figure 2 . The Norwegian HT1 patients diagnosed between 1980 and 2011.  
 
29 of these patients are of Norwegian descent, and one patient is an immigrant from 
another European country. Altogether nine patients have died. Eight of them died 
before NTBC was available. The ninth died of acute HT1 in the newborn period after 
receiving only a few doses of NTBC. Of the remaining 21 patients, six were liver 
transplanted before NTBC was available. One patient, seven years old at the time of 
diagnosis and start of NTBC treatment, received a liver transplant because of 
hepatocellular carcinoma after two years on NTBC treatment. The remaining 14 HT1 
patients are presently on NTBC treatment.  
 It has recently been suggested to classifiy HT1 clinically in three groups based 
on the age at onset of symptoms: before 6 months  of age (acute form), between 6 
and 12 months of age (subacute form), after 12 months of age (chronical form) 
(Chakrapani A, Gissen, and McKiernan 2011). This corresponds well, but not 
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perfectly with the clinical pictures. In a previous report we designated only 
phenotypes at the extremes of the clinical spectrum as “acute” or “chronic” to reveal 
an eventual genotype – phenotype correlation (Rootwelt et al. 1996). Thus many 
patients were categorized as intermediate in the midle category. Only one of our 
patients is categorized in the midle group based on the age at onset of symptoms. 
 Of a total of 29 patients of Norwegian descent 18 were diagnosed after 12 
months of age. One was diagnosed between 6 and 12 monts of age, and four were 
diagnosed before 6 months of age. Four patients did not have an acute form of HT1, 
but further classification is difficult because accurate clinical information is missing.  
Two asymptomatic patients, one diagnosed at birth and one at seven months of age, 
cannot be fully clinically classified, because they were found as a result of an already 
diagnosed sibling and not because of their own symptoms (Figure 8).  Altogether, the 
chronic form of HT1 dominates in Norway with hypophosphatemic rickets as the most 
common clinical symptom leading to diagnosis.  
 An expanded newborn screening program which includes HT1 was started in 
Norway March 1st, 2012. The relatively high proportion of chronic HT1 in the 
Norwegian population, possibly with milder biochemical findings at birth, may cause 
an increased risk of false negative screening results. The incidence of HT1 and the 
disease causing Fah mutations in the Norwegian population are the subjects of 
publication I. 
DNA alterations and the phenomenon of self-induced 
correction
Different DNA alterations have been demonstrated in tissue from HT1 patients. In 
cultured skin fibroblasts from one patient with the chronic form of HT1, chromosomal 
instability with increased chromosomal breakage was demonstrated (Gilbert-Barness, 
Barness, and Meisner 1990).  No chromosomal abnormalities were seen in 
fibroblasts from a patient with the acute form of HT1.(Wilson et al. 1994) In another 
study a murine HT1 model demonstrated a spectrum of different DNA alterations in 
hepatocytes. The DNA alterations were distributed as follows: 20 % point mutations, 
30 % small deletions and insertions and, 50 % large DNA alterations (Manning et al. 
1999). The high frequency of point mutations was emphasized by Kvittingen and 
coworkers in 1994 with the striking demonstration of self-induced correction of 
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disease causing mutations in liver tissue from the majority of HT1 patients (Kvittingen 
et al. 1994). In liver tissue from 16 of 19 HT1 patients investigated, 
immunohistochemical staining with an antibody against Fah surprisingly 
demonstrated a mosaic pattern of immunonegative and immunopositive cells 
indicating production of Fah protein in clones of cells. Molecular analyses 
demonstrated a correction of one of the causative point mutations in the 
immunopositive cell clones. Liver tissue from four of the patients was investigated. 
One patient was compound heterozygous for the splice site mutation IVS12+5g>a 
and an unknown mutation. One patient was compound heterozygous for IVS12+5g>a 
and the nonsense mutation G1069>T (E357X). One patient was homozygous for the 
combined splice site and missense mutation G1009>A (G337S). One patient was 
homozygous for the splice site mutation G192>T. IVS12g>a was corrected in the 
compound heterozygous patients. In one patient four different nodules were 
investigated, all of them showing the same reversion. Three of the patients showed 
the splice site reversion g (wildtype) >a (inborn mutation) >g (reversion), one patient 
showed the reversion CAG>CAT>CAG. Later studies have confirmed the reversion 
g>a>g and additionally demonstrated the reversion CAG>CGG>CAG (Demers et al. 
2003;Dreumont et al. 2001;Poudrier et al. 1998).  In vivo reversion of inherited 
mutations back to normal has also later been described in other diseases like 
adenosine deaminase deficiency (Ariga et al. 2001;Arredondo-Vega et al. 
2002;Hirschhorn et al. 1994;Hirschhorn et al. 1996), Fanconi anemia (Gregory, Jr. et 
al. 2001;Gross et al. 2002;Lo, Jr. et al. 1997;Waisfisz et al. 1999) and epidermiolysis 
bullosa (Darling et al. 1999;Jonkman et al. 1997;Pasmooij et al. 2007;Schuilenga-Hut 
et al. 2002).  
This phenomenon illustrates a principle of clonal expansion based on a 
competitive growth advantage. When a genetic alteration, random or otherwise, 
corrects one of the primary mutations, expression of functional Fah is restored. 
Consequently, the cell is able to eliminate the toxic metabolites FAA and MAA. The 
cell is “cured” with respect to HT1 and has gained a tremendous competitive growth 
advantage compared to the neighbouring dysfunctional cells. This also supports the 
idea of cell autonomy in HT1. FAA and MAA, reacting with other molecules before 
they are able to leak out of the cell, will have little effect on the “cured” 
immunopositive cell clone. And vice versa, the restored function in the reverted 
nodules cannot alleviate the dysfunction in the remaining immunonegative cells. 
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Investigations in a murine HT1 model receiving gene therapy have confirmed and 
elucidated this hypothesis. Transplanted wildtype hepatocytes showed a strong 
competitive growth advantage and were able to fully repopulate the livers of fah-/- 
mice (Overturf et al. 1996). The reversion phenomenon has been understood as a 
result of arbitrary events in the rapidly replicating cells. Thus, HT1 and the other 
conditions mentioned above, all affect tissues with sufficiently high cell turnover to 
allow for selection of reverted cells to occur. Other explanations of the reversion 
phenomenon seen in HT1 patients could be possible, but seem more unlikely. 
Homologous recombination is excluded at least in the homozygous patients where 
mutation correction has been demonstrated. An early embryonic mutation in a HT1 
patient could give a mosaic pattern of hepatocytes, but the high incidence of self-
induced corrections among the HT1 patients makes it unlikely. Repopulation by 
maternal cells after transplacental transport would be an interesting explanation, and 
could explain the high incidence and early occurrence of mutation correction in HT1 
patients. But presence of the paternal mutation in the immunopositive nodules, as we 
have seen in 50 % of the cases in our laboratory, excludes this as a predominant 
explanation of the phenomenon. Furthermore, no evidence of maternal cell 
colonization was seen in four homozygous HT1 patients in one study (Bergeron et al. 
2004).  
Another explanation could be a new, second site mutation in the Fah gene 
stabilizing the transcript or protein sufficiently to provide immunoreactive material and 
enough enzyme activity to give the corrected cell a selective growth advantage. This 
is investigated in publication II.  
The pattern of corrected nucleotides in the hepatocytes from HT1 patients 
could reflect mutation liability as a sequence dependent phenomenon (Seeberg and 
Fuchs 1990). This is investigated in publication III. 
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 DNA damage 
DNA in living cells is continuously exposed to damaging events like hydrolysis, 
oxidation and methylation caused by the normal metabolism. Figure 3 shows three 
examples of DNA damaging events. 
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Figure 3 shows examples of spontaneous DNA damage through oxidation, 
methylation and hydrolysis producing 5-hydroxycytosine, 6-methylguanine and uracil, 
respectively. 
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In a single human cell under normal physiology 50.000 -100.000 DNA lesions occur 
each day (Friedberg EC 2006b). Table 2 gives an overview over the endogenous 
sources, frequencies and types of DNA lesions.  
 
Table 2. Numbers of endogenous DNA lesions arising and repaired in mammalian 
cells in 24 hours (adapted from. (Friedberg EC 2006b)). 
Endogenous source  Lesions pr day
50,000Single strand breaks 
Hydrolysis 
    Depurination 18,000
    Depyrimidination 600
    Cytosine deamination 500
    5-mC deamination 50
Oxidation 
    8oxoG 1,000 -2,000
    Ring saturated pyrimidines  2,000
    Lipid peroxidation products  1,000
Nonenzymatic methylation  
by S-adenolsylmethionine 
    7-mG 6,000
    3-mA 1,200
    1-mA, 3mC 200
Nonenzymatic methylation  
by nitrosated polyamines and peptides 
    6-mG 20 - 100
 
The most quantitatively important damage forms are single strand breaks and 
depurination by hydrolysis. Hydrolysis can also result in depyrimidination and 
deamination. Other damaging metabolic events are oxidation, nonenzymatic 
methylation and replication errors. Reactive oxygen species (ROS) may damage the 
DNA molecule in different ways introducing strand breaks, abasic sites or modified 
DNA bases either in the DNA strand or those existing as free nucleotides. More than 
80 different aberrant bases produced by ROS have been described (Bjelland and 
Seeberg 2003). Oxidation of guanine in the 8-position yields the mutagenic lesion 
8oxoG, which is one of the most abundant oxidative DNA base alterations. Guanine 
is prone to oxidation due to its low oxidation potential. 8oxoG pairs with both adenine 
and cytosine and may therefore lead to the transversion GC > AT. The content of 
8oxoG in purified samples of genomic DNA is detectable with HPLC with 
electrochemical detection and is frequently used as an oxidative stress marker. 
Thymine glycol and cytosine glycol are important pyrimidine lesions. The latter is in 
equilibrium with 5-hydroxycytosine (5ohC) which is the dehydrated form of cytosine 
glycol. Thymine glycol and 5ohC are cytotoxic and mutagenic, respectively. The ring 
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opening of purines is another important form of ROS induced damage and yields 
formamidopyrimidine (faPy). The faPy lesion may block the process of DNA 
polymerases. Recognition and initiation of catalysis of different oxidative DNA bases 
lesions is reviewed in  (Dalhus et al. 2009). 
DNA damage is also induced by exogenous sources such as UV-radiation, 
and alkylating- and oxidizing-agents. 
DNA repair 
To maintain DNA integrity all lesions in the DNA molecule have to be repaired. In 
Table 3 the sources of DNA base damages are listed with the most common 
corresponding lesions, major repair mechanisms and prototypical repair enzymes in 
human cells. 
 
Table 3. DNA damaging agents, lesions, repair pathways and prototypical human 
repair enzymes (adapted from (Dalhus et al. 2009)) . 
 
Damaging agent Prototypical lesions Major repair 
mechanism
Prototypical human repair 
enzymes 
Alkylating agents 6-mG DR Tranferases: Agt 
 1-mA DR Oxidoreductases: Abh2 
 3-mA, 3mG, 7-mA, 7-mG BER Glycosylases: Aag 
    
Hydrolysis Abasic sites BER Endonucleases: Ape1 
 Deamination forming uracil BER Glycosylases: Ung 
 Deamination forming hypoxanthine NIR Endonucleases: EndoV 
    
ROS 8-oxoG. faPyA/G, TG, 5-ohC, 
DHU, DHT 
BER Gylcosylases: Ogg1, Nth1 
 DHU,DHT, 5-ohC NIR Endonucleases: Ape1 
    
Replication errors (a) Base mismatches MMR Mismatch proteins:  
(b) Insertion/deletion loops   MutS/  
    
UV radiation Bulky adducts NER Xpa –Xpf + others 
 CPDs, 6-4PDs DR Photolyases 
Cells have several strategies to overcome the problems of DNA damage and its 
potentially fatal effect on transcription and replication. Different types of DNA 
damages require different repair pathways. Replication errors are repaired by the 
mismatch repair pathway (MMR) (Harfe and Jinks-Robertson 2000). The lethal 
double DNA strand breaks are repaired either by non homologous end joining 
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(NHEJ) or homologous recombination (O'Driscoll and Jeggo 2006). Five DNA 
polymerases in human cells by-pass different DNA lesions to ensure that the cell 
survives, but at the cost of a higher error frequency (Lehmann 2006) The complete 
repair of a DNA lesion is an alternative and vital strategy to maintain DNA integrity. 
Repair of DNA lesions was initially described in the bacterium E.coli, and many repair 
mechanisms are conserved from bacteria to man. Several mechanisms of direct 
repair and excision repair are well characterized in many species. Direct repair 
removes the lesion directly in one reaction without removing any part of the DNA 
molecule. As an example the aberrant methyl group in position six on O6-
methylguanine (6-mG) is removed by the specific enzyme 6-mG DNA-transferase 
(Figure 5). In base excision repair (BER) a part of the DNA molecule that surrounds 
the damage, from one to several bases, is removed, and the DNA strand is 
subsequently reconstructed. This process has several steps, requires different 
enzymes and can repair a broad spectrum of different DNA base lesions. The BER 
pathway removes one to ~10 bases (Liu et al. 2007). The nucleotide excision repair 
(NER) pathway is responsible for the repair of larger distortions in the helical 
structure of DNA, removing 20-30 bp at the lesion (Fleck and Nielsen 2004). NER is 
divided into global genome repair (GGR) and transcription-coupled repair (TCR). 
TCR maintains actively transcribed genes by excising DNA damage that blocks the 
RNA polymerase. GGR does not differentiate between transcribed and silenced 
genes.  
 
Base excision repair 
BER is considered to be the main pathway for repair of DNA base lesions in the cells. 
It consists of a complex series of reactions which takes place continuously. The base 
lesions require different DNA glycosylases to initiate the BER pathway. Several DNA 
glycosylases display overlapping substrate affinity ensuring less vulnerability to 
inherited enzyme deficiencies and emphasize the importance of the BER pathway.  
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Figure 4 The BER pathway (adapted from (Dalhus et al. 2009)) (LP: long patch) The 
steps are described in detail in the text below. 
 
The BER pathway (Figure 4) is initiated by hydrolysis of the glycosylic bond between 
the base and the sugar (a and e). The bifunctional DNA glycosylase substitutes the 
damaged base with an activated amine moiety. The intrinsic AP lyase activity cleaves 
the DNA backbone 3 of the lesion (b) and the remaining unsaturated fragment is a 
substrate for AP endonucleases (c). The monofunctional DNA glycosylase creates an 
abasic site with an activated water molecule (e), which is a substrate for AP 
endonucleases (f). 2-deoxyribose-5-phosphate (dRP), the remaining 5-sugar 
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fragment, is removed by dRP lyase activities (g). The resulting gap is then filled (d) 
either with a single nucleotide (short patch repair) or by 2 or more nucleotides (long 
patch repair). The remaining nick is sealed by DNA ligase activity.  
 In mammalian cells there are 11 known glycosylases (Barnes and Lindahl 
2004), which are classified according to enzyme activity as monofunctional or 
bifunctional. Alternatively, glycosylases can be divided into four distinct groups based 
on the three dimensional folds/motifs: (1) helix-hairpin-helix motif (HhH) (2) helix-
2turn-helix motif (H2TH) (3) Udg fold and (4) Aag fold (Friedberg EC 2006a). Table 4 
shows an overview of the human glycosylases and their major substrates.  
 
Table 4, The 11 human Glycosyleses and their major substrates (from (Barnes and 
Lindahl 2004). 
Protein Major or significant substrates 
Ung Uracil 
Smug Uracil, 5-oh-meU 
Tdg Thymine, U:G, ethenocytosin:G 
Mbd4 Thymine:G, U:G, Thymine:6-mG 
Myh 8oxoG:A, 2-ohA:G 
Ogg1 8oxoG:C 
Nth1 Thymine glycol, Dihydrouracil, faPyG 
Neil1 As Nth1, faPyA, 5S, 6R TG isomer, 8oxoG 
Neil2 Overlap with Nth1/Neil1 
Neil3 oxidation products of 8ohG 
Aag 3mA, hypoxanthine, ethenoadenine 
 
Ogg1: Ogg1 is the major DNA glycosylase for the removal of 8oxoG:C lesions in 
eukaryotic cells (Bjoras et al. 1997;van der Kemp et al. 1996). In humans there are 
two different forms of the protein located either in the cell nucleus or in the 
mitochondria (Nishioka et al. 1999). Ogg1 belongs to the HhH super family of 
glycosylases. The crystal structures of the apoenzyme and the enzyme in complex 
with DNA have been determined (Bjoras et al. 2002;Bruner, Norman, and Verdine 
2000)  Ogg1 is a bifunctional enzyme with the potential to remove the base and 
cleave off the sugar phosphate backbone at an AP site. However, it appears that 
Ogg1 primarily acts as a monofunctional DNA glycosylase (Morland et al. 2005). 
After cleavage of the N-glycosylic bond the 8oxoG residue remains for a short while 
in the recognition pocket and acts as a catalytic cofactor in the second reaction 
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(Fromme et al. 2003). ogg1 deficient mice have no distinct phenotype. The level of 
8oxoG is higher in hepatocytes from ogg1-/- than in cells from wildtype mice and 
increases continuously to become 3 -10 fold higher than in wildtype (Klungland et al. 
1999). The spontaneous mutation rate, despite the 8oxoG accumulation is only 
increased three fold in ogg1-/- mice (Arai et al. 2003), and the 8oxoG lesions are 
slowly removed from ogg1-/- cells indicating overlapping enzyme activities (Osterod et 
al. 2001). ogg1-/- mice do not show increased tumour development, and the same is 
the case for myh-/- mice, but double knockout mice ogg1-/- myh -/- are significantly 
predisposed to tumours particularly of the lung, ovarian, lymphoma varieties. (Xie et 
al. 2004). 
The “GO-system”: The cell has developed a complex defence against the 
mutagenic effect of 8oxoG (Figure 6). In addition to Ogg1, two other enzymes 
contribute to the detection and removal of 8oxoG/8oxodGTP. Together this defence 
cooperation is called “The GO-system” (The 8oxoG lesion is also called “GO”) 
(Fowler et al. 2003;Michaels and Miller 1992). If Ogg1 misses an 8oxoG:C lesion 
Myh gives Ogg1 a second chance. Myh recognises the mispaired 8oxoG:A (the 
mutagenic consequence of 8oxoG:C) and removes the adenine and incorporates a C 
opposite 8oxoG which is further processed in the Ogg1 repair pathway (Slupska et al. 
1996;Takao et al. 1999). Mth1 contributes to DNA integrity indirectly by “cleaning” the 
pool of free nucleotides before they are incorporated into the DNA strand. Mth1 
hydrolyses 8oxo-dGTP to 8oxo-dGMP which can not be incorporated into DNA 
(Nakabeppu et al. 2006). 
Nth1, Neil1 and Neil2 are glycosylases in mammalian cells that remove 
oxidized and fragmented pyrimidine residues. Endonuclease III (Nth) was first 
described in E.coli as an endonuclease able to create nicks in DNA from cells 
exposed to DNA damaging treatment (Radman 1976;Strniste and Wallace 1975). 
Later Nth was described as a bifunctional protein with both glycosylase and AP lyase 
activities (Cunningham and Weiss 1985;Katcher and Wallace 1983). Spontaneous 
mutation rates increase only moderately in Nth-/- cells, which can be explained by the 
presence protein endonuclease eight (Nei) which acts as a backup DNA repair 
system (Saito et al. 1997).  
E.coli cells lacking Nei do not demonstrate any phenotype. Double mutants 
lacking both Nth and Nei are hypersensitive to gamma-radiation (Jiang et al. 
1997;Saito et al. 1997). There is a parallel situation in human cells. Nth1 in human 
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cells is the ortholog to Nth and acts on many substrates (Table 4), and Nth1 knockout 
mice have no clinical phenotype (Takao et al. 1999). Endonuclease VIII like proteins 
(Neil1, Neil2 and Neil3) act as DNA repair systems (Bandaru et al. 2002;Hazra et al. 
2002a;Hazra et al. 2002b;Rosenquist et al. 2003;Takao et al. 2002). The substrate 
specificity of Neil1 and Neil2 are overlaps with Nth1 but also repairs some additional 
DNA lesions (Table 4). A neil1 knockout mouse model has shown a metabolic 
phenotype with variable pentetrance (Sampath et al. 2011), a neil3 knockout mouse 
model has shown profound neuropathology (Sejersted et al. 2011), neither of them 
have demonstrated tumour development. A neil2 knockout mouse model has not 
been described so far. A double knockout nth1-/-neil1-/- mouse model developed 
pulmonary and hepatocellular tumours with much higher incidence than either of the 
single knockout, nth1-/- and neil1-/- (Chan et al. 2009).  
 Udg: Uracil-DNA-glycosylases (Udg) removes uracil from DNA and was first 
described by Lindahl (1974) in E.coli. Udgs occur in most species and can be divided 
into eight different families based on the precise type of uracil damage (substrate) 
they remove (Friedberg EC 2006a). Of these eight Udg families four are found in 
mammalian cells: Ung, Smug1. Mbd4 and Tdg (Table 4). Structural studies show the 
same conserved core in the different Udg families reflecting common catalytic 
properties. The differences in the flanking parts of the proteins reflect the substrate 
specificity (uracil, 5-OH-methyluracil, uracil-mismatches etc.). Ung removes uracil 
from both single stranded and double stranded DNA. It occurs in two distinct forms 
from alternatively spliced mRNA from the same gene: Ung1 is sited in the 
mitochondria and Ung2 in the cell nucleus (Krokan et al. 2001). The major function of 
Ung in mammalian cells is to remove uracil when it is accidentally paired with 
adenine. The repair capacity is huge compared with other known glycosylases. In 
E.coli Ung catalyses the removal of 800 uracil residues from DNA per minute and 
there are ~300 Ung molecules present per cell (Lindahl et al. 1977). In contrast to 
many other glycosylases mouse models ung knockout mice demonstrate a specific 
pathological phenotype by developing B-cell lymphomas (Nilsen et al. 2003). Both 
the high repair turnover number and the fatal consequence of ung knockout 
emphasise the importance of uracil repair. 
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 Direct DNA repair 
Alkylating damage in DNA is both mutagenic and cytotoxic. It may be repaired by 
alkyltransferases. As previously mentioned the specific lesion is removed directly in 
one reaction without removing any part of the DNA molecule.   
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Fig 5. The direct repair of O6methylguanine by O6-DNA-methyltransferase.  
(Ada: adaptive response protein) 
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genes (ada, ogt) encode 6-mG DNA methyltransferases in E.coli. Similar enzymes 
are characterised in many species with a high degree of homology. 6-mG DNA 
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damage. However the process is energetically very expensive because an entire 
protein is expended for each lesion.  
  The lesions 3-methylcytosine and 1-methyladenine are repaired by oxidative 
demethylation catalysed by AlkB proteins. The reaction is dependent on  O2, Fe++ 
and -keto-glutarate and yields succinate and CO2 (Begley and Samson 2003;Falnes 
2004;Falnes, Johansen, and Seeberg 2002). In humans the ABH1 gene was 
identified and cloned in 1996 (Aas et al. 2003). Two other human homologues were 
identified in 2002 (Duncan et al. 2002). 
 
Spontaneous mutations
Impaired DNA repair predisposes for introduction of permanent mutations (Friedberg 
EC 2006a). DNA lesions can lead to base mispairing and a permanently altered 
nucleotide sequence. This is of particulary interest in respect to HT1 because of the 
high frequency of true reversions (see defention in the dscussion). The highly 
mutagenic lesion 8oxoG is exemplified in Figure 6.    
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 Figure 6.  Repair of the 8oxoG lesion. The oxidative lesion 8oxoG can lead to base 
mispairing and a permanently altered nucleotide sequence in two different ways.
1. 8oxoG is a substrate for several DNA glycosylases, of which Ogg1 is the main 
enzyme. If such a lesion is not repaired 8oxoG can basepair with adenine instead of 
cytosine during replication. The 8oxoG:A pair may still be repaired in two steps by 
Myh which removes adenine and subsequently 8oxoG by Ogg1 or another 
glycosylase. If 8oxoG:A is not repaired before a second round of replication it will 
result in a permanently altered nucleotide sequence in one of the daughter cells. T:A 
is a normal base pair and “invisible” to the DNA repair systems, thus a permanent 
mutation (G:C > A:T)  is established (red circle on the left). 
2. Nucleotides can also be damaged prior to incorporation in the DNA strand. The 
repair enzyme Mth1 “cleans” the pool of free nucleotides by converting 8oxoGTP to 
8oxoGMP. If free 8oxoG is incorporated by a DNA polymerase it will base pair with 
adenine instead of cytosine. The enzymes Myh and Ogg1 will subsequently “repair” 
the oxidative lesion and thereby produce the point mutation A:T > G:C (red circle on 
the right).
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 Human Disease and Deficient DNA repair  
Several inborn syndromes are linked to impairments of different parts of the DNA 
repair system. Increased vulnerability to DNA damaging agents is a typical 
consequence. Tumour development and premature aging are typical of these 
diseases. Deficient DNA repair is suggested to be a central part of the aging process 
in general. Impaired DNA repair also plays a role in non-mitotic tissue. Alzheimers 
disease is an example of a neurodegenerative condition in which impaired BER may 
be a part of the pathophysiology. 
Some diseases affect the NER system. Xeroderma pigmentosum (XP) is one 
of the most studied diseases. This is a rare autosomal recessive disease 
characterized by dermatological symptoms like photosensitivity, actinic keratoses and 
early cutaneous tumour development in sun-exposed areas of the body. Different 
ocular and neurological symptoms are also frequently seen. XP is genetically and 
phenotypically complex and involves at least seven genes which affect the NER 
system. The cells become vulnerable to DNA damaging agents resulting in increased 
mutagenicity and cell death. Onset of symptoms occurs in early childhood, and the 
therapy is protection against sunlight (Bootsma et al. 2001). Defective repair of DNA
strand breaks: Ataxia telangiectasia (AT) is a rare autosomal recessive disease with 
an incidence of 1 in 40.000 live births. It is characterized by cerebellar ataxia, 
progressive mental retardation, small blood vessel dilation, immune dysfunction and 
neoplasms of the lymphoreticular system. The cells of AT patients are extremely 
sensitive to ionizing radiation, but not to UV radiation or DNA damaging agents that 
require NER. The patients have mutations in the ATM gene (ataxia telangiectasia 
mutated) which codes for a large 350 kDa protein consisting of 3056 amino acids. 
The protein is located mainly in the nucleus and is recruited to double-strand breaks 
and influences cell division (Chun and Gatti 2004). Defective DNA helicase: Bloom 
syndrome (BS) is a rare disease of autosomal recessive inheritance. It is 
characterized by a general tendency towards tumour development, thus the cancers 
may derive from many different tissues. The tumour types include leukaemia, 
lymphoma, Wilms tumour, medulloblastoma, osteogenic sarcoma, breast cancer, 
lung cancer etc (Willis and Lindahl 1987). DNA replication: Hereditary non polyposis 
colon cancer (Lynch syndrome) is typically characterised by impaired mismatch 
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repair and microsatelite instability, i.e. instability of simple repeated sequences. 
Slippage in the simple repeated sequences of the DNA-strand during replication 
leads to replicates of different lengths. In Lynch syndrome these replication errors are 
not effectively repaired. The patients have increased risk for many different cancer 
types, but especially colorectal cancer (Fishel et al. 1993). Four genes are involved, 
and the inheritance is autosomal dominant with varying penetrance. 
Several studies show increased amount of oxidative DNA lesions in both 
neurons and lymphocytes of patients with Alzheimers disease (Reviewed in (Lovell 
and Markesbery 2007)).  The increase is significant in both early and late stages of 
the disease suggesting that DNA oxidation is an early event in the disease 
progression. Other studies show a reduced capacity for DNA repair in a variety of 
lesions suggesting that impaired DNA repair contributes to the neurodegeneration 
observed in Alzeheimers disease. 
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Impaired DNA repair in HT1, a hypothesis 
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Figure 7. DNA instability in hepatocytes of HT1 patients. DNA is damaged by 
increased oxidative stress, the presence of alkylating agents and impaired DNA 
repair.
 
Figure 7 shows how accumulation of DNA damage can lead to increased mutation 
rates and cancer development in hepatocytes in HT1 patients. In general 
accumulation of DNA damage can result in cancer development through increased 
genetic instability and activation of oncogenes and inactivation of tumor suppressor 
genes. In HT1 patients the accumulation of oxidative DNA damage is possibly 
increased due to decreased levels of glutathione (Jorquera and Tanguay 1997). 
Reduced DNA repair capacity will accelerate this process. Our results in paper III 
suggest that inhibition of the BER pathway by FAA can lead to cancer development 
in HT1 hepatocytes. 
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Aims of the present study 
The purpose of this thesis is to increase the understanding of genetical mosaicism 
and the frequent development of hepatocellular carcinoma in HT1 patients by:    
 
 
 describing the molecular basis of HT1 in Norwegian patients. 
 investigating DNA instability in HT1. 
 describing the pattern of self-induced corrections in Norwegian HT1 patients 
 describing of DNA damage in liver tissue from HT1 patients.  
 searching for alternative explanations for the reversion phenomenon. 
 measuring glycosylase activity under the influence of HT1 metabolites. 
 measuring metyltransferase activity under the influence of HT1 metabolites. 
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Summary of published results  
Paper I
28 Norwegians have been diagnosed with hereditary tyrosiaemia type I (HT1) over 
the last 30 years. In this study, 19 of these patients who had not previously been 
genetically characterized, are investigated. Three novel small deletions were found 
(NM_000137.1(FAH): c.615delT, p.Phe205LeufsX2, NM_000137.1(FAH): c.744delG, 
p.Pro249HisfsX55 and NM_000137.1(FAH):c835delC pGln279ArgfsX25), all of them 
leading to a change in the reading frame and a premature stop codon. 51 of the 56 
disease causing alleles are hereby genetically characterized, identifying 9 different 
disease causing mutations in the Norwegian population. 65 % of the Norwegian HT1 
patients are compound heterozygous for different mutations. Thus, the relatively high 
incidence of HT1 in Norway of 1 in 74,800 live births is not due to single founder 
effects or high incidence of parental consanguinity.  
 
Paper II
Many patients with HT1 have a mosaic pattern of Fah immunopositive and negative 
nodules in liver tissue. This phenomenon has been explained by a spontaneous 
reversion of the mutation in one allele to a normal genotype, but only a few nodules 
have been examined. In this study we report a Norwegian patient, compound 
heterozygous for the mutations IVS12g+5a and G1009A, with liver mosaicism, but 
with an immunopositive nodule in which both primary mutations were intact. In the 
immunopositive hepatocytes of this nodule genetic analyses showed a new mutation 
C1061A 6 bp upstream of the primary mutation IVS12g+5a in the FAH gene. The 
splicing defect caused by the primary mutation is most likely suppressed by the new 
mutation due to improvement of the splicing site. In the same liver we demonstrate 
another nodule of regenerating immunopositive tissue due to reversion of one of the 
primary mutations to a normal genotype. Together with the original cells this results in 
a triple mosaicism of hepatocytes with 1, 2 or 3 point mutations in the FAH gene. 
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 Paper III
Several reports suggest that intracellular accumulation of intermediates of tyrosine 
catabolism such as fumarylacetoacetate (FAA) and succinylacetone (SA) is an 
important cause of the liver and kidney pathology in HT1 patients. In this work we 
examined the effect of FAA and SA on DNA glycosylases initiating base excision 
repair, which is the most important pathway for removing mutagenic DNA base 
lesions. In vitro assays monitoring enzymatic activity of three different human DNA 
glycosylases, Ogg1, Neil1 and Neil2 demonstrated that FAA, but not SA, strongly 
inhibited base removal. These DNA glycosylases initiate excision of a broad range of 
mutagenic base lesions. Thus, it appears that inhibition of DNA glycosylases by FAA 
in HT1 patients increases mutagenesis and may contribute to hepatocellular 
carcinoma and somatic mosaicism.  
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 Discussion
The incidence of HT1 in Norway 
Norway is one of the areas in the world with an above average incidence of HT1. The 
incidence is by far the highest in the Quebec region of Canada with 1 patient in 
16.786 living births. The incidence in Scandinavia is stated to be 1 patient in 100.000 
living births in one of the most cited textbooks of the field of inborn errors of 
metabolism (The metabolic & Molecular Bases of Inherited Disease, online version 
2009). The reference in this book for the Scandinavian incidence is however a 
chapter by S. Halvorsen in another textbook from as early as 1980 (Halvorsen 1980) 
The estimate is made only a few years after the first descriptions of the condition Fah 
deficiency, when the diagnostics were under development and before the treatment 
with NTBC was established. No recalculations of this number have been published in 
scientific papers, but Eli Anne Kvittingen suggested a higher number, 1 patient in 
50.000 newborns, in her thesis from 1986. This estimate was also based on only a 
few years of HT1 diagnostics in Norway. After another 25 years it was possible to 
estimate the incidence better (paper I), and it seems that Halvorsen’s and 
Kvittingen’s numbers were too low and too high respectively. Our point estimate 
suggests 1 patient in 75.000 living births. The number of patients (14) diagnosed in 
our laboratory between 1991 and 2010 is however still low, and this makes our new 
estimate uncertain as well. If one extra or one less patient had been diagnosed in the 
period, the incidences would have been 1 in 70.000 and 1 in 80.000 live births, 
respectively. The incidence in the Quebec region of Canada is due to a complex 
founder effect, the possible elevated incidence in the Middle East is probably due to 
consanguinity (Imtiaz et al. 2011). The elevated incidence in Norway is caused by the 
coincidence of many different pathogenic mutations in the population. Figure 8 shows 
how the origins of the Norwegian HT1 patients (29) are distributed in the country.  
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IVS12+5g>a  x5
Unknown x3
IVS12+5g>a x4
G337S x10
Unknown x2
IVS12+5g>a x 4
G337S x 2
P249HHfsX55 x 4
E357X x 1
Q279RRfsX25 x 2
Unknown x 1
IVS12+5g>a x 5
G337S x 1
G337S
F205LLfsX2
IVS12+5g>a 
P342L
IVS12+5g>a x 2
A134D x 2
P249HHfsX55 x 1
W262X x 1
P249HHfsX55 x 2
Age at diagnosis
<  6 months (acute)
6 – 12 months (subacute)
> 12 months (chronic)
At birth without symptoms
Unclassified
Figure 8. The distribution of HT1 patients in Norway. The numbers (x N) given 
identify the number of alleles. 
 
There is only one patient diagnosed from the middle parts of Norway, and 67 % of 
the patients live in three counties: Hordaland, Telemark and Finnmark. The three 
mutations IVS12+5g>a, G337S and P249HfsX55 constitute 73 % of the disease 
alleles identified in Norway. The most common mutation worldwide IVS12+5g>a is 
also the most common in Norway (40,4 %). The other mutations: 26,9 % G337S, 
13,5 % P249HfsX55, 3,8 % Q279RfsX25, E357X and A134D, 1,9 % F205LfsX2, 
W262X and P342L. Comments on methodology: Standard Sanger sequencing has 
been used to characterize the unknown FAH alleles. PCR and RFLP assays have 
been used to detect specific mutations. These methods are approved and routine in 
our laboratory. Therefore method employing realtime PCR were not developed for 
analyses of these rare mutations in the FAH gene. 
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Genetic mosaicism
The intragenic suppressor mutation (paper II) gives an alternative explanation to self-
induced reversion and elucidates different points regarding the immunopositive 
nodules in livers of HT1 patients. It supports the assumption of high mutagenic 
activity in HT1 hepatocytes and the assumption that random point mutations explain 
the occurrence of immunopositive nodules. It indicates that the mosaic pattern of 
hepatocytes in HT1 patients may be more complex than previously assumed.  
Kvittingen’s report from 1994 of the self-induced reversion to normal genotype 
in hepatocytes from HT1 patients was surprising (Kvittingen et al. 1994). Genetic 
mosaicism per se had been well known for decades in advance. A spontaneous 
reversion of a disease causing mutation had also previously been descried (Yang et 
al. 1988), but only as a single event caused by gene rearrangements. “The shocking 
news” was the frequent occurrence of immunopositive cell clones in the liver samples 
(in 16 of 19 patients), “all” apparently genetically corrected through random mutations 
(samples from 4 patients were genetically characterized). Self-induced corrections of 
inborn errors have later been described in several other conditions like Fanconi 
anemia, Bloom syndrome and epiodermiolysis bullosae (Table 5). The reversions 
does not occur as frequently in these diseases as it does in HT1 patients,  although a 
relatively high frequency (~20 %) has been found in epidermiolysis bullosae (EB) 
(German et al. 1977). The cellular conditions and the molecular mechanisms behind 
the corrections are however not necessarily the same for each condition. Table 5 
shows that the described reversions are of different types, and that they take place in 
different tissues and in different diseases. 
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 Table 5 (adapted from (Hirschhorn 2003) ) 
Disease Tissue Type of reversion 
HT1 Liver Single nucleotide 
Second site mutation   
   
ADA-SCID   B cells 
T cells 
Single nucleotide 
Second site mutation   
  
X linked SCID T cells Single nucleotide 
CpG hot spot  
   
Wiskott-Aldrich (X-L) T cells 
Lympocytes 
Single nucleotide  
Second site mutation   
Second site del/ins   
   
Bloom Syndrome Fibroblasts 
Lymphocytes 
Lymphoid cell lines 
Slippage   
Single nucleotide  
   
Epidermiolysis Bullosae Skin Mitotic gene conversion 
Second site del/ins   
   
FANC A  Blood cells 
Lymphoid cell lines 
Second site insertions   
Ins/del repeat hot spot 
Single nucleotide   
Single nucleotide & repeat   
slippage   
   
FANC C   Blood cells 
Lymphoid cell lines 
Intragenic recombination   
Not intragenic recombination 
Second site CpG hot spot   
The diseases for which intragenic recombination and gene conversion can be excluded are written in bold face. 
ADA: adenosin deaminase, SCID: severe cmbined immunodeficiency,X-L: X-linked, Fanc: fanconi anemia,  
del: deletion, ins: insertion 
 
Hirshorn suggests that there could be a possible common reversion mechanism in 
cases with the same type of reversion and when intragenic recombination and gene 
conversion can be excluded. The diseases for which such patients have been 
described are written in bold face in Table 5. The hypothesis of a sequencespecific 
common cause of reversion in these cases is interesting; however, many 
characteristics of HT1 differ significantly from the other diagnoses. Thus a common 
cause of DNA instability is not easy to conceive despite of common types of mutation 
reversion. HT1 phenotype characteristics including self-induced corrections and 
frequent cancer development in hepatocytes are connected to, and probably caused 
by, the specific accumulating metabolites. In X-linked SCID, Bloom syndrome and EB 
there are no known metabolite accumulation. DNA instability therefore must have 
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other causes. The competitive growth advantage of corrected/healed HT1 
hepatocytes is “obvious” since the accumulation of metabolites of strong toxicity is 
prevented. Competitive growth advantage has been described after infusion of 
healthy cells (wildtype) in a X-linked SCID mouse model (Kume et al. 2002), but this 
pathological situation is also different from HT1. X-linked SCID is caused by 
mutations in the IL2RG gene and subsequent deficiency of the cytokine receptor 
common-gamma-chain. The deficiency leads to disturbed interleukin signalling 
including lack of cellular response to growth signals via IL-7 and other cytokines. 
Thus the growth advantage of infused wildtype cells in the X-L-SCID mouse is due to 
the regulation of a cellular signal system, not because of elimination of DNA 
damaging agents. 
True reversions and second site reversions 
In the literature the reversion of a primary mutation is sometimes called a “back 
mutation” or a “true back mutation” (Ellis, Ciocci, and German 2001;Hirschhorn 
2003;Pasmooij et al. 2005). Kvittingen’s report from 1994 of the self-induced 
reversion to normal genotype was an early example of a such “back mutation” in 
human cells. A suppressor mutation is by definition “a mutation that counteracts the 
effects of another mutation” (Anthony JF Griffiths 2000). The result is a “second site” 
revertant. The detection of a suppressor mutation (paper II) in the FAH gene was an 
early example of such second site reversions.  
The triple mosacism in the liver of one HT1 patient discussed in paper II 
implies that a more complex mosaic pattern of hepatocytes is possible in other 
patients as well. Two cell clones with different back mutations in a single liver are 
possible in compound heterozygous patients. Different types of second site reversion 
are also imaginable. It is important to bear in mind that only a slight improvement of 
the Fah activity would be sufficient for the hepatocyte to obtain a selective growth 
advantage. The Fah pseudodeficiency illustrates this. An individual homozygous for 
the mutation R341W in the FAH gene showed very low enzyme activity but had no 
biochemical or clinical symptoms of HT (Rootwelt, Brodtkorb, and Kvittingen 1994). 
The need of only a slight improvement of the Fah activity increases the number of 
theoretically significant nucleotide alterations. 
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Possible types of suppressor mutations 
We describe a second site suppressor mutation in one cell clone (paper II). The 
primary splice site mutation was suppressed by a new point mutation that improved 
the efficiency of the affected splicing site.  Other alterations in the same splicing site 
could however also improve splice site efficiency. A theoretical example: Online 
scoring systems for 5’ splice site efficiency (see details in the next section) predict 
that the theoretical mutation G1065>A in the FAH gene improves the splice site 
efficiency to about the same degree as the mutation (C1061>A) discussed in paper 
II. 
 The mutation G337S in the FAH gene introduces a cryptic splice site. An 
additional point mutations may weaken the cryptic splice site. 
 All but two of the proteinogenic amino acids have two or more triplets of 
nucleotides coding for them. In patients with the FAH mutation Arg381Gly, 
c.1141A>G a new point mutation could restore the amino acid sequence. (AGA (Arg) 
> AGT (Gly) > CGT (Arg)) Arg381Gly, is however, not among the mutations detected 
in Norwegian patients. 
 An additional missense mutation elsewhere in the FAH gene can introduce an 
amino acid substitution that might counter fatal effects on protein structure by the 
primary mutation. 
 A disrupted reading frame because of deletions/insertions of nucleotide(s) can 
be restored with other deletions/insertions. 
 In addition to intragenic nucleotide alterations, extragenic suppressor 
mutations are theoretically possible. An enzyme knockout upstream of Fah in the 
tyrosine degradation pathway would “cure” the cell just like the drug NTBC. The toxic 
metabolites would no longer be produced. The chance of such a knockout occurring 
is low because both alleles of the other gene must be disrupted; two independent 
events must take place instead of one. On the other hand there are many possible 
genetic alterations that could be effective. Knockout of one of three genes (TAT, 
4HPPD and HAO) in the tyrosine degradation pathway would block the production of 
toxic metabolites. Furthermore many genetic alterations in each gene might disrupt 
the protein function. Such cell clones would however not be detected using antibody 
against Fah.   
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Extended investigation of hepatocyte nodules 
We have investigated 18 Fah immunopositive hepatocyte nodules in addition to the  
nodules previously reported (paper II, (Kvittingen et al. 1994)). Five HT1 patients 
were investigated. No suppressor mutations were revealed; only reversions of 
primary mutations (true back mutations) were detected (unpublished data). 
 
Table 6. Fah immunopositive hepatocyte clones in HT1 patients. Reverted alleles are 
indicated in bold face. 
Nodules 
investigated 
Detected 
reversion  Not conclusive 
Maternal 
mutation 
Paternal 
mutation 
Patient 1 1 1 0 G337S IVS12+5g>a 
Patient 2 6 4 2 IVS12+5g>a P249HfsX55 
Patient 3 4 4 0 IVS12+5g>a E357X 
Patient 4 1 0 1 P249HfsX55 W262X 
Patient 5 6 5 1 F205LfsX2 G337S
 
Table 6 shows the number of investigated nodules from each patient. The reverted 
mutations are written in bold face. The reversion (g>a>g) of the mutations 
IVS12+5g>a and G337S was detected in 14 immunopositive nodules. No clear 
results were obtained in 4 nodules because of unsatisfactory technical quality. Only 
one type of back mutation was detected in each patient. This can be a coincidence 
because a low number of patients and nodules were investigated. It could also be 
due to the mutation types. Patients 2 and 5 are compound heterozygous for a point 
mutation and a small deletion. The frequencies of compensatory point mutations and 
deletions/insertions are not necessarily equal. It is also possible that the different 
immunopositive areas in the liver sections are derived from the same expanding 
immunopositive cell clone.  
 Complex mosaicisms have been reported in two patients with another 
autosomal recessive disorder; the dermatological disease epidermiolysis bullosa 
(Pasmooij et al. 2005).  Patient 1 and 2 in were compound heterozygous for the 
nonsense mutation 3781C>T in the COL17A1 gene and the frame shift mutations 
4424 – 5insC and 1706delA respectively. Both patients showed several discrete 
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patches of functionally restored skin, and genetic analyses of the different areas 
demonstrated different types of genetic reversions. Patient 1 showed a true back 
mutation of 3781C>T and a second site small deletion 4463delG (restores the 
reading frame). Patient 2 showed a second site suppressor mutation 3782G>C 
(prevents the nonsense mutation) from one skin area and two distinct gene 
conversions in two other areas.  
 The studies on HT1 and EB show that both the phenomenon of complex 
mosaicism and genetic reversion may not be so rare, but the characteristics of EB 
differ from HT1 in several ways. As previously pointed out there is no known 
accumulating metabolite connected to the disease. The mosaicism is suggested to 
be caused by random embryonic mutations, but the mutation rate is not increased. 
The restored skin areas remain unchanged throughout life, thus the mosaicism is not 
due to clonal selection and expansion. 
 
Sequence requirements for spliceosome function 
A new mutation (C1061A) 6 bp upstream of the primary mutation IVS12g+5a in the 
FAH gene is described in paper II. The splicing defect caused by the primary 
mutation is most likely suppressed by the new mutation due to improvement of the 
splicing site according to in silico analysis of the most common splice sites in the 
mammalian genome (Burset, Seledtsov, and Solovyev 2000). Several algorithms 
have been developed to calculate a splice site score to predict the effect of mutations 
in the splicing site and are available online. Table 7 shows the 5’ splice site scores 
from four algorithms: maximum entropy (MAXENT) multiple dependence 
decomposition (MDD), Markov's model (MM) and a Weight Matrix Model (WMM) 
(Houdayer et al. 2008). The results are consistent with the analysis performed in 
paper II.  
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Table 7. Splicing efficiency estimates at the 5’ donor splice site of  intron12 in the 
FAH gene. Exonic and intronic nucleotides are shown in upper- and lowercase 
letters, respectively.
 Splice site sequence  MAXENT: MDD MM WIMM 
FAH wildtype (wt) CCGgtgagt 10,90 15,68 10,63 9,35 
immunonegative tissue CCGgtgaat 4,89 6,48 6,16 5,90 
immunopositive tissue CAGgtgaat 6,60 10.78 7,40 8,24 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) 
 
The algorithms produce absolute values for the 5’ splice site, but the relative changes 
in splice site strengths are considered more important (Yeo and Burge 2004). All four 
algorithms predict that the new mutation in immunopositive tissue improves splicing 
efficiency. The average score for immunopositive tissue is 72 % of wildtype whereas 
the score for immunonegative tissue is 52 % of wildtype .  
 
Comments on methodology: The effect of the suppressor mutation described in 
paper II was made probable by calculations concerning the splicosome. Site-directed 
in vitro mutagenesis would have been necessary to obtain a valid biological proof. 
However the findings were considered to be convincing at the time of publication 
without in vitro mutagenesis because of the in silico evaluation and the complete 
absence of other genetical differences in the FAH gene between the Fah positive and 
negative tissue. Consistent 5’ splice site scores from the expanded in silico analysis 
(Table 7) supports this assumption. 
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Impaired Base Exission Repair (BER) in HT1 
It is not obvious if or to what extent glutathione reduction and the alkylating activities 
of FAA and MAA explain the high frequency of point mutations, cancer, and the 
reversion phenomenon in HT1 hepatocytes. As shown in Figure 7 reduced DNA 
repair capacity will accelerate the accumulation of DNA damage and increase the 
instability of DNA. To elucidate the role of DNA repair in HT1 we have investigated 
the activity of four glycosylases (Ogg1, Neil1, Neil2 and Ung2) and one 
methyltransferase (6-mG methyltransferase ) under the influence of FAA and SA.  
The pattern of reversions 
Deficiency of specific repair enzymes would increase the probability for specific 
sequence dependent changes. The pattern of reversions may therefore reflect the 
eventual type of impaired DNA repair activity. Six examples of true back mutations 
are previously published (Kvittingen et al. 1994) (Dreumont et al. 2001) Additionally 
we have detected back mutations in 14 immunopositive nodules from five patients 
(Table 6). Eighteen reversions are of the type: g>a>g, one is a>g>a and one is c>t>c. 
The second site reversion discussed in paper II is c>a. The number of patients and 
nodules are too small to conclude if this is a representative distribution of reversion 
types. A majority of the reversion g>a>g must be expected because the mutation 
IVS12g>a is the most common in the patient population. The pattern shows however 
that several types of point mutations (a>g, g>a, t>c and c>a) take place in HT1 
hepatocytes. If this reflects reduced protection against specific DNA lesions, 
enzymes with substrates of more than one type must be impaired. We have 
investigated four glycosylases (Ogg1, Neil1, Neil2 and Ung2) that together cover a 
broad battery of substrates (Table 4). 
In addition we have investigated 6-mG DNA methyltransferase 
(Mycobacterium tuberculosis) for two reasons: Firstly 6-mG is a highly mutagenic 
damage (Lawley 1989), and secondly the enzyme has an important sulfhydryl group 
in the active site (Daniels et al. 2004) which could be attacked by FAA. 
 
51
FAA inhibits the first step of the BER. 
BER is the most important pathway for removing mutagenic DNA base lesions. In 
paper III we demonstrate that FAA inhibits the three glycosylases Ogg1, Neil1 and 
Neil2 strongly. Ogg1 is the major DNA glycosylase for removal of 8-oxoG opposite C 
and Neil1 function as a backup activity (Bjoras et al. 1997;Morland et al. 2002). 8-
oxoG is as previously stated one of the most common mutagenic adducts that result 
from oxidative DNA damage (Shibutani, Takeshita, and Grollman 1991). Neil1 and 
Neil2 remove oxidized pyrimidines which are mutagenic lesions as well (Feig, 
Sowers, and Loeb 1994). The inhibition by FAA was particularly strong on Neil1 and 
Neil2. Significant inhibition was detected with only a small excess of FAA. The 
approximate molar ratios at 50 % inhibition were; FAA/Neil1 and  ~3 FAA/Neil2 ~1. 
This reflects a particularly efficient inhibition mechanism. The approximate molar ratio 
at 50 % inhibition of Ogg1 was FAA/Ogg1 ~6000 which also suggests efficient 
inhbition. The inhibition of three glycosylases means a probable significant inhibition 
of the first step of the BER pathway in HT1 hepatocytes because of the enzyme’s 
overlapping substrate specificity and their function as a back up for each other. 
These results suggest that inhibition of Ogg1, Neil1 and Neil2 by FAA in liver cells of 
HT1 patients increase mutagenesis.  Knockout mouse models for different DNA 
glycosylases support this assumption. The single knockouts (neil1-/-, ogg1-/-, nth1-/- 
or myh-/-) show no or modest increase in cancer development. Several double 
knockouts show however increased mutagenesis and carcinogenesis (Chan et al. 
2009;Xie et al. 2004). The double knockout ogg1 -/-myh-/- mouse model started to 
develop tumors at the age of two months (Xie et al. 2004). nth1-/-neil1-/- mice even 
developed hepatocellular tumours (Chan et al. 2009) which are of particularly interest 
in HT1. We have not investigated Nth1 in our study, but the structural similarity with 
Ogg1 suggests that Nth1 may be inhibited by FAA as well. Nth1 has overlapping 
substrate specificity with Neil1 and Neil2. See “Future perspectives” for further 
possible investigations.  
The inhibition of the glycosylases may be due to structural changes of the 
proteins caused by adduct formation or competition between FAA and oxidative DNA 
base lesions for the active site in these enzymes. See “Future perspectives” for 
possible further investigations.  
FAA did not inhibit Ung2, and SA did not inhibit any of the investigated 
enzymes. 
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 BER and HT1 pathophysiology 
 Our study elucidates the role of FAA in the HT1 pathophysiology. FAA induced BER 
impairment fits well into the theories of accumulating ROS induced DNA damage in 
HT1 hepatocytes. The increased accumulation of oxidative base lesions, due to 
reduced glycosylase activity, has both mutagenic and cytotoxic consequences, thus 
the impaired BER pathway contributes to the understanding of the mutagenicity, the 
cancer development and the hepatocyte decay in HT1 patients. The fact that only 
FAA and not SA acts as an inhibitor fits with the cell autonomous model. FAA affects 
the cells of the organ in which it is produced; no HT1 patients are described with 
primary cancer in any other tissue. The inhibition of the purified glycosylases Ogg1, 
Neil1 and Neil2 is demonstrated in vitro. We have attempted to measure Ogg1, Neil1 
and Neil2 DNA glycosylase activity in protein extracts from transplanted HT1 livers, 
but the level of glycosylases in the protein extracts were below the detection limit.  
 
Content of 8oxoG in HT1 hepatocytes 
Detection of DNA damage in HT1 hepatocytes which corresponds to the specific 
base lesions removed by Ogg1, Neil1 and Neil2 would have confirmed the impact of 
our findings and strongly supported our hypothesis. We performed a pilot study that 
showed a significant increase in 8oxoG accumulation in genomic DNA from one HT1 
patient compared with one control sample, but the subsequent investigations could 
not confirm the results from the pilot study. We have measured the 8oxoG content in 
20 DNA samples from 6 liver transplant HT1 patients and compared them with 31 
liver samples from 8 control liver transplant patients (cancer coli). 
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Figure 9. Analyses of 8oxoG content in hepatocytes of HT1 patients and controls. 
The columns show the mean value with 95 %- confidence interval.
 
The results were difficult to interpret. The average 8oxoG:C-content was 19 % higher 
in the samples from HT1 patients compared to the controls, but the confidence 
interval was broad and the difference between HT1 samples an the control samples 
was not statistically significant (p = 0.5 Mann-Whitney-U test). Varying amounts of 
DNA damage in hepatocytes from HT1 patients could perhaps reflect the 
heterogeneity of HT1 hepatocytes. But it could also reflect poor age matching 
between our patient samples and control samples. The control samples used in this 
study were collected over a period of two years prior to analysis. Our HT1 patient 
samples are 15 – 20 years old with one exception (5 years old).   
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 Investigation of Ogt  
Purified 6-mG methyltransferase from Mycobacterium tuberculosis was investigated 
under the influence of increasing amounts of FAA and SA.  There is a high degree of 
homology between the human enzyme and the enzyme from M. tuberculosis. No 
significant decrease in enzyme activity was detected for either of the HT1 
metabolites. The active site of 6-mG methyltransferase contains a cysteine unit 
(Daniels et al. 2004), thus an inhibiting effect of FAA would not have been surprising. 
Lack of inhibition suggests that the SH-group of the cysteine is protected within the 
protein structure. 
 
The methyltransferase assay 
N-[H3]-N-methyl-N’--nitro-N-nitrosourea (MNU; 1.5 Ci mmol-1) was used to prepare 
methylated calf thymus DNA (6000 d.p.m. g-1 DNA). The methyltransferase activity 
was measured in a reaction buffer (90 mM Tris, 90 mM Borate, 2 mM EDTA (TBE 
buffer)) with 500 fmol Ogt and 1.5 g MNU treated calf thymus DNA in a total volume 
of 3 ml at 37°C for 60 min. Increasing concentrations of FAA or SA were added to the 
reaction mixtures. The protein was precipitated by incubating with 100 l of 10 mg/ml 
BSA (in TBE buffer) and 1 ml of 4 M perchloric acid (HClO4) for 30 min at 70°C. The 
precipitate was spun down at 4000 rpm for 20 min. The pellet was washed with 4 ml 
of 1M HClO4 and resolved in 0.4 ml of 0.1 M HCl. The samples were transferred into 
tubes containing  ULTIMA GOLDTM MV scintillation liquid (Packard BioScience B. V., 
Netherlands), and the radioactivity was measured in a scintillation cou  nter (Liquid 
Scintillation Analyzer, TRI-CARB 2900TR). 
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Comments on previous studies on DNA instability in HT1
Cytogenetic studies on skin fibroblasts from one HT1 patient were reported in 1990 
by Gilbert-Barnes et al. (Gilbert-Barness, Barness, and Meisner 1990). The patient 
was a girl with chronic HT1 who died from hepatocellular carcinoma at four years of 
age. Increased chromosomal breakage affecting 71 % of the cells was demonstrated 
and related to the alkylating agents FAA and MAA. On this basis genetic instability 
was suggested to be a part of the pathophysiology and carcinogenesis in HT1. The 
importance of the chromosomal breakage in fibroblasts in this study seems however 
to be unclear for several reasons. Fibroblasts are most likely not exposed to FAA and 
MAA because tyrosine is exclusively degraded in the liver. SA is distributed 
throughout the body, but the relation to cancer development is less clear because 
primary tumours have only been detected in the liver of HT1 patients. The study was 
based on only 14 cells from one patient and has not been confirmed in later work 
(Wilson et al. 1994).  
Prieto-Alamo et al (1998) described reduced DNA ligase activity in protein 
extracts from HT1 fibroblasts (Prieto-Alamo and Laval 1998). In a separate assay SA 
was shown to inhibit T4 DNA ligase in vitro at high concentrations (100μM). Thus 
inhibition by SA was suggested as an explanation for the reduced DNA ligase activity 
in the protein extracts. However the SA concentration was not measured in the 
protein extracts. The results from this study have not been verified in other studies, 
thus both the role of DNA ligase in HT1 and the influence of SA on DNA ligase seem 
unclear. FAA was not investigated in this study. 
More recently van Dyke et al have used a comet assay to examine whether 
BER was inhibited in cells treated with SA or p-hydroxyphenylpyruvate (van Dyk et al. 
2010). However it is unclear from this work whether DNA glycosylase activities are 
affected by SA or p-hydroxyphenylpyruvate. A carcinogenic effect of p-
hydroxyphenylpyruvate is not likely. This metabolite is not specific for HT1 and it 
increases to a much higher level in tyrosinaemia type II (Mitchell et al. 2001), a 
condition that is not associated with cancer development. FAA is not tested in this 
study. In a recent paper, van Dyk showed reduced gene expression of Ogg1 in 
lymphocytes from two HT1 patients, indicating that down-regulation of DNA 
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glycosylases at the transcriptional level could impair BER of oxidative damage (van 
Dyk E. and Pretorius 2011).  
Future perspectives 
To further investigate the DNA repair capacity in HT1 more DNA enzymes should be 
tested under the influence of HT1 metabolites. The activities of Nth1, Myh and Mth1 
should be investigated to elucidate the total effect of HT1 metabolites on the defence 
against oxidative DNA damage. Additionally it would be of interest to investigate the 
defence against methylating DNA damage provided by the Aag DNA glycosylase for 
example. Both FAA and SA should be investigated as potential inhibitors. 
Detection of oxidative DNA damage in HT1 hepatocytes would support our 
findings in paper III. Investigation of aberrant methylation and hydrolytic damage to 
the DNA molecules would complete the picture. MS-MS technology makes it possible 
to detect all sorts of damage modifications to the DNA molecule. With appropriate 
age matched control samples it would be of interest to investigate methylation, 
oxidative and hydrolytic damage in DNA extracts of hepatocytes from HT1 patients.  
In paper III we suggest a strong inhibiting effect of FAA on glycosylase activity. 
Our studies do not reveal the mechanism of this inhibition. Changes in protein 
structure may be a part of the explanation. Thus it would be of interest to investigate 
structural changes to Ogg1, Neil1, and Neil2 and eventually other DNA repair 
enzymes. Electrophoretic mobility shift assays can be used to detect protein-DNA 
interactions. MS analyses may also reveal structural changes of the proteins after 
FAA exposure.   
To develop a combined fah-/- glycosylase-/-  knockout mouse would perhaps be 
the ideal way to explore the effect of FAA on BER capacity. Two fah deficient mouse 
models have been engineered by others (Grompe et al. 1993;Russell, Russell, and 
Kelly 1979). In our laboratory, lines of different double and triple  knockout mice are 
developed. A cooperation to develop a combined fah-/- and glycosylase -/-   knockout 
mouse line would be of interest. Three possibilities are the triple knockouts: fah-/-
ogg1-/- mutY-/- , fah-/- neil1-/- neil2-/- and fah-/- neil1-/- nth1-/-. 
There is still one unknown FAH mutation in the Norwegian HT1 population. 
One of our patients has only had the paternal mutation identified after sequencing 
(paper I). The other mutation may affect the promoter region of the FAH gene. No 
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FAH promoter mutations have yet been identified in HT1 patients. A promoter 
mutation can be hard to exclude. Most promoter mutations are located within the first 
500 nucleotides upstream of the start codon, although regulatory regions may also 
be found 10kb or more upstream of the gene (de Vooght, van, and van Solinge 
2009). Furthermore, mutations deep into introns or far downstream of the coding 
region may also impair gene function.  
 
 
Conclusion
Our studies give a new estimate of the incidence of hereditary tyrosinaemia type I 
(HT1) in Norway, and we have described the molecular basis of HT1 in the 
Norwegian population in more detail than previous reports with three novel small 
deletions and all together nine different disease causing mutations (paper I). HT1 is 
characterized by a high hepatocellular mutation frequency, hepatocellular mosaicism 
and frequent development of hepatocellular carcinoma. In paper II we explore the 
phenomenon of self-induced genetic correction in HT1 hepatocytes and describe a 
new mechanism behind the reversion phenomenon. A triple mosaicism was detected 
in one patient. In one cell clone the primary splice site mutation was suppressed by a 
new point mutation due to improvement of the splicing site. The triple mosaicism of 
hepatocytes supports the assumption of an increased frequency of point mutations in 
HT1. The studies on DNA glycosylases suggest a common pathophysiology behind 
the high frequency of point mutations and cancer development (paper III). Three 
glycosylases with overlapping substrate specificity were strongly inhibited by FAA in
vitro. Thus the first step of the base excision repair (BER) pathway is probably 
suppressed in hepatocytes in HT1. Such inhibition of BER is associated with both 
increased mutation frequency and increased cancer development. Impaired BER 
may thus be an important factor in the pathophysiology of HT1. 
58
 References
References 
 
Aas, P. A., Otterlei, M., Falnes, P. O., Vagbo, C. B., Skorpen, F., Akbari, M., 
Sundheim, O., Bjoras, M., Slupphaug, G., Seeberg, E., & Krokan, H. E. 2003, 
"Human and bacterial oxidative demethylases repair alkylation damage in both RNA 
and DNA", Nature, vol. 421, no. 6925, pp. 859-863. 
Allard, P., Grenier, A., Korson, M. S., & Zytkovicz, T. H. 2004, "Newborn screening 
for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of 
succinylacetone extracted from dried blood spots", Clinical Biochemistry, vol. 37, no. 
11, pp. 1010-1015. 
Anthony JF Griffiths, J. H. M. D. T. S. R. C. L. a. W. M. G. 2000, "Glossary," in An
Introduction to Genetic Analysis., 7th edition edn, New York: W. H. Freeman. 
Arai, T., Kelly, V. P., Komoro, K., Minowa, O., Noda, T., & Nishimura, S. 2003, "Cell 
proliferation in liver of Mmh/Ogg1-deficient mice enhances mutation frequency 
because of the presence of 8-hydroxyguanine in DNA", Cancer Res, vol. 63, no. 14, 
pp. 4287-4292. 
Ariga, T., Oda, N., Yamaguchi, K., Kawamura, N., Kikuta, H., Taniuchi, S., 
Kobayashi, Y., Terada, K., Ikeda, H., Hershfield, M. S., Kobayashi, K., & Sakiyama, 
Y. 2001, "T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency 
showed the restoration of ADA activity resulted from the reversion of an inherited 
mutation", Blood, vol. 97, no. 9, pp. 2896-2899. 
Arora, N., Stumper, O., Wright, J., Kelly, D. A., & McKiernan, P. J. 2006, 
"Cardiomyopathy in tyrosinaemia type I is common but usually benign", 
J.Inherit.Metab Dis., vol. 29, no. 1, pp. 54-57. 
Arredondo-Vega, F. X., Santisteban, I., Richard, E., Bali, P., Koleilat, M., Loubser, M., 
Al Ghonaium, A., Al Helali, M., & Hershfield, M. S. 2002, "Adenosine deaminase 
deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: 
decline in revertant T lymphocytes during enzyme replacement therapy", Blood, vol. 
99, no. 3, pp. 1005-1013. 
BABER, M. D. 1956, "A case of congenital cirrhosis of the liver with renal tubular 
defects akin to those in the Fanconi syndrome", Arch.Dis.Child, vol. 31, no. 159, pp. 
335-339. 
Bandaru, V., Sunkara, S., Wallace, S. S., & Bond, J. P. 2002, "A novel human DNA 
glycosylase that removes oxidative DNA damage and is homologous to Escherichia 
coli endonuclease VIII", DNA Repair (Amst), vol. 1, no. 7, pp. 517-529. 
59
Barnes, D. E. & Lindahl, T. 2004, "Repair and genetic consequences of endogenous 
DNA base damage in mammalian cell", Annual Review of Genetics, vol. 38, pp. 445-
476. 
Bateman, R. L., Bhanumoorthy, P., Witte, J. F., McClard, R. W., Grompe, M., & 
Timm, D. E. 2001, "Mechanistic inferences from the crystal structure of 
fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor", Journal of 
Biological Chemistry, vol. 276, no. 18, pp. 15284-15291. 
Baumann, U., Preece, M. A., Green, A., Kelly, D. A., & McKiernan, P. J. 2005, 
"Hyperinsulinism in tyrosinaemia type I", J.Inherit.Metab Dis., vol. 28, no. 2, pp. 131-
135. 
Begley, T. J. & Samson, L. D. 2003, "AlkB mystery solved: oxidative demethylation of 
N1-methyladenine and N3-methylcytosine adducts by a direct reversal mechanism", 
Trends in Biochemical Sciences, vol. 28, no. 1, pp. 2-5. 
Berger, R., Van, F. H., Taanman, J. W., De, V. H., & Agsteribbe, E. 1987, "Type I 
tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein 
in tissues and cell extracts", Pediatr res, vol. 22, no. 4, pp. 394-398. 
Bergeron, A., Lettre, F., Russo, P., Morissette, J., & Tanguay, R. M. 2004, "No 
evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I 
patients", Gastroenterology, vol. 127, no. 5, pp. 1381-1385. 
Bjelland, S. & Seeberg, E. 2003, "Mutagenicity, toxicity and repair of DNA base 
damage induced by oxidation", Mutat.Res, vol. 531, no. 1-2, pp. 37-80. 
Bjoras, M., Luna, L., Johnsen, B., Hoff, E., Haug, T., Rognes, T., & Seeberg, E. 1997, 
"Opposite base-dependent reactions of a human base excision repair enzyme on 
DNA containing 7,8-dihydro-8-oxoguanine and abasic sites", EMBO Journal, vol. 16, 
no. 20, pp. 6314-6322. 
Bjoras, M., Seeberg, E., Luna, L., Pearl, L. H., & Barrett, T. E. 2002, "Reciprocal 
"flipping" underlies substrate recognition and catalytic activation by the human 8-oxo-
guanine DNA glycosylase", Journal of Molecular Biology, vol. 317, no. 2, pp. 171-
177. 
Bootsma, D., Kraemer, K. H., Cleaver, J. E., & Hoeijmakers, J. H. J. 2001, 
"Nucleotide Excision Repair Syndromes: Xeroderma Pigmentosum, Cockayne 
Syndrome, and Trichothiodystrophy," in The Metabolic & Molecular Bases og 
Inherited Disease, 8 edn, C. R. Scriver et al., eds., McGraw-Hill Book Co., New York 
N.Y., pp. 677-703. 
Bopp, F. 1849, "Einiges über albumin, caseïn und fibrin.", Ann.Chem.Pharm., vol. 69, 
no. 16. 
Bruner, S. D., Norman, D. P., & Verdine, G. L. 2000, "Structural basis for recognition 
and repair of the endogenous mutagen 8-oxoguanine in DNA", Nature, vol. 403, no. 
6772, pp. 859-866. 
60
Burset, M., Seledtsov, I. A., & Solovyev, V. V. 2000, "Analysis of canonical and non-
canonical splice sites in mammalian genomes", Nucleic Acids Research, vol. 28, no. 
21, pp. 4364-4375. 
Chakrapani A, Gissen, P., & McKiernan, P. 2011, "Disorders of Tyrosine 
Metabolism," in Inborn Metabolic Diseases, 5th edn, J. M. Saudubray, G. van den 
Berghe, & J. H. Walter, eds., Springer-Verlag, Berlin Heidelberg New York, pp. 265-
276. 
Chan, M. K., Ocampo-Hafalla, M. T., Vartanian, V., Jaruga, P., Kirkali, G., Koenig, K. 
L., Brown, S., Lloyd, R. S., Dizdaroglu, M., & Teebor, G. W. 2009, "Targeted deletion 
of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence 
of novel carcinogenic oxidative damage to DNA", DNA Repair (Amst), vol. 8, no. 7, 
pp. 786-794. 
Chun, H. H. & Gatti, R. A. 2004, "Ataxia-telangiectasia, an evolving phenotype", DNA
Repair (Amst), vol. 3, no. 8-9, pp. 1187-1196. 
Coufalik, A. H. & Monder, C. 1980, "Regulation of the tyrosine oxidizing system in 
fetal rat liver", Archives of Biochemistry and Biophysics, vol. 199, no. 1, pp. 67-75. 
Cunningham, R. P. & Weiss, B. 1985, "Endonuclease III (nth) mutants of Escherichia 
coli", Proc.Natl.Acad.Sci.U.S.A, vol. 82, no. 2, pp. 474-478. 
Dalhus, B., Laerdahl, J. K., Backe, P. H., & Bjoras, M. 2009, "DNA base repair--
recognition and initiation of catalysis", FEMS Microbiology Reviews, vol. 33, no. 6, 
pp. 1044-1078. 
Daniels, D. S., Woo, T. T., Luu, K. X., Noll, D. M., Clarke, N. D., Pegg, A. E., & 
Tainer, J. A. 2004, "DNA binding and nucleotide flipping by the human DNA repair 
protein AGT", Nat.Struct.Mol.Biol., vol. 11, no. 8, pp. 714-720. 
Darling, T. N., Yee, C., Bauer, J. W., Hintner, H., & Yancey, K. B. 1999, "Revertant 
mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-
restoring mutation", J.Clin.Invest, vol. 103, no. 10, pp. 1371-1377. 
de Andrade, R. B., Gemelli, T., Rojas, D. B., Funchal, C., Dutra-Filho, C. S., & 
Wannmacher, C. M. 2011, "Tyrosine inhibits creatine kinase activity in cerebral 
cortex of young rats", Metab Brain Dis., vol. 26, no. 3, pp. 221-227. 
De Braekeleer, M. & Larochelle, J. 1990, "Genetic epidemiology of hereditary 
tyrosinemia in Quebec and in Saguenay-Lac-St-Jean", American Journal of Human 
Genetics, vol. 47, no. 2, pp. 302-307. 
de Vooght, K. M., van, W. R., & van Solinge, W. W. 2009, "Management of gene 
promoter mutations in molecular diagnostics", Clinical Chemistry, vol. 55, no. 4, pp. 
698-708. 
Dehner, L. P., Snover, D. C., Sharp, H. L., Ascher, N., Nakhleh, R., & Day, D. L. 
1989, "Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver", 
Human Pathology, vol. 20, no. 2, pp. 149-158. 
61
Demers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. 2003, "Frequent mutation 
reversion inversely correlates with clinical severity in a genetic liver disease, 
hereditary tyrosinemia", Human Pathology, vol. 34, no. 12, pp. 1313-1320. 
Dickson, A. J., Marston, F. A., & Pogson, C. I. 1981, "Tyrosine aminotransferase as 
the rate-limiting step for tyrosine catabolism in isolated rat liver cells", FEBS Letters, 
vol. 127, no. 1, pp. 28-32. 
Dreumont, N., Poudrier, J. A., Bergeron, A., Levy, H. L., Baklouti, F., & Tanguay, R. 
M. 2001, "A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, 
responsible for hereditary tyrosinemia, acts as a splicing mutation", BMC Genet., vol. 
2, no. 1, p. 9. 
Duncan, T., Trewick, S. C., Koivisto, P., Bates, P. A., Lindahl, T., & Sedgwick, B. 
2002, "Reversal of DNA alkylation damage by two human dioxygenases", 
Proc.Natl.Acad.Sci.U.S.A, vol. 99, no. 26, pp. 16660-16665. 
Ellis, N. A., Ciocci, S., & German, J. 2001, "Back mutation can produce phenotype 
reversion in Bloom syndrome somatic cells", Human Genetics, vol. 108, no. 2, pp. 
167-173. 
Endo, F., Kubo, S., Awata, H., Kiwaki, K., Katoh, H., Kanegae, Y., Saito, I., Miyazaki, 
J., Yamamoto, T., Jakobs, C., Hattori, S., & Matsuda, I. 1997, "Complete rescue of 
lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase 
and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the 
tyrosine catabolic pathway", Journal of Biological Chemistry, vol. 272, no. 39, pp. 
24426-24432. 
Endo, F. & Sun, M. S. 2002, "Tyrosinaemia type I and apoptosis of hepatocytes and 
renal tubular cells", J.Inherit.Metab Dis., vol. 25, no. 3, pp. 227-234. 
Fallstrøm,SP, Lindblad,B, Lindstedt,S, and Steen,G. Hereditary tyrosinemia - 
fumarylacetoacetase deficiency. Pediatr res 13, 78. 1979.  
Ref Type: Abstract 
Falnes, P. O. 2004, "Repair of 3-methylthymine and 1-methylguanine lesions by 
bacterial and human AlkB proteins", Nucleic Acids Research, vol. 32, no. 21, pp. 
6260-6267. 
Falnes, P. O., Johansen, R. F., & Seeberg, E. 2002, "AlkB-mediated oxidative 
demethylation reverses DNA damage in Escherichia coli", Nature, vol. 419, no. 6903, 
pp. 178-182. 
Feig, D. I., Sowers, L. C., & Loeb, L. A. 1994, "Reverse chemical mutagenesis: 
identification of the mutagenic lesions resulting from reactive oxygen species-
mediated damage to DNA", Proc.Natl.Acad.Sci.U.S.A, vol. 91, no. 14, pp. 6609-6613. 
Fellman, J. H., Fujita, T. S., & Roth, E. S. 1972, "Assay, properties and tissue 
distribution of p-hydroxyphenylpyruvate hydroxylase", Biochimica et Biophysica Acta, 
vol. 284, no. 1, pp. 90-100. 
62
Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., 
Kane, M., & Kolodner, R. 1993, "The human mutator gene homolog MSH2 and its 
association with hereditary nonpolyposis colon cancer", Cell, vol. 75, no. 5, pp. 1027-
1038. 
Fleck, O. & Nielsen, O. 2004, "DNA repair", Journal of Cell Science, vol. 117, no. Pt 
4, pp. 515-517. 
Fowler, R. G., White, S. J., Koyama, C., Moore, S. C., Dunn, R. L., & Schaaper, R. 
M. 2003, "Interactions among the Escherichia coli mutT, mutM, and mutY damage 
prevention pathways", DNA Repair (Amst), vol. 2, no. 2, pp. 159-173. 
Friedberg EC, W. G. S. W. W. R. S. R. E. T. 2006a, "Base excision repair," in DNA
Repair and Mutagenesis, Second edn, ASM Press, Washington DC, pp. 169-226. 
Friedberg EC, W. G. S. W. W. R. S. R. E. T. 2006b, "DNA Damage," in DNA Repair 
and Mutagenesis, W. G. S. W. W. R. S. R. E. T. Friedberg EC, ed., ASM Press, 
Washington, DC, pp. 9-69. 
Fromme, J. C., Bruner, S. D., Yang, W., Karplus, M., & Verdine, G. L. 2003, 
"Product-assisted catalysis in base-excision DNA repair", Nature Structural Biology, 
vol. 10, no. 3, pp. 204-211. 
Fujinami, S., Hijikata, Y., Shiozaki, Y., & Sameshima, Y. 1990, "Profiles of plasma 
amino acids in fasted patients with various liver diseases", Hepatogastroenterology, 
vol. 37 Suppl 2, pp. 81-84. 
German, J., Schonberg, S., Louie, E., & Chaganti, R. S. 1977, "Bloom's syndrome. 
IV. Sister-chromatid exchanges in lymphocytes", American Journal of Human 
Genetics, vol. 29, no. 3, pp. 248-255. 
Gilbert-Barness, E., Barness, L. A., & Meisner, L. F. 1990, "Chromosomal instability 
in hereditary tyrosinemia type I", Pediatr Pathol., vol. 10, no. 1-2, pp. 243-252. 
Greenbeg D.M. 1969, "Tyrosine degradation," in Metabolic Pathways, vol. 3 
Greenberg D.M., ed., Academic Press, New York, pp. 144-153. 
Gregory, J. J., Jr., Wagner, J. E., Verlander, P. C., Levran, O., Batish, S. D., Eide, C. 
R., Steffenhagen, A., Hirsch, B., & Auerbach, A. D. 2001, "Somatic mosaicism in 
Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem 
cells", Proc.Natl.Acad.Sci.U.S.A, vol. 98, no. 5, pp. 2532-2537. 
Grompe, M. 2001, "The pathophysiology and treatment of hereditary tyrosinemia type 
1", Seminars in Liver Disease, vol. 21, no. 4, pp. 563-571. 
Grompe, M., Al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. 
G., & Soriano, P. 1993, "Loss of fumarylacetoacetate hydrolase is responsible for the 
neonatal hepatic dysfunction phenotype of lethal albino mice", Genes and 
Development, vol. 7, no. 12A, pp. 2298-2307. 
Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., 
Torres-Ramos, C. A., Ou, C. N., & Finegold, M. 1995, "Pharmacological correction of 
63
neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type 
I", Nature Genetics, vol. 10, no. 4, pp. 453-460. 
Gross, M., Hanenberg, H., Lobitz, S., Friedl, R., Herterich, S., Dietrich, R., Gruhn, B., 
Schindler, D., & Hoehn, H. 2002, "Reverse mosaicism in Fanconi anemia: natural 
gene therapy via molecular self-correction", Cytogenet.Genome Res, vol. 98, no. 2-3, 
pp. 126-135. 
Halvorsen, S. 1980, "Screening for disorders of tyrosine metabolism," in Neonatal 
Screenings for Inborn Errors of Metabolism, H. Bickel, R. Guthrie, & G. Hammerson, 
eds., Springer-Verlag, New York, p. 45. 
Harfe, B. D. & Jinks-Robertson, S. 2000, "DNA mismatch repair and genetic 
instability", Annual Review of Genetics, vol. 34, pp. 359-399. 
Hazra, T. K., Izumi, T., Boldogh, I., Imhoff, B., Kow, Y. W., Jaruga, P., Dizdaroglu, M., 
& Mitra, S. 2002a, "Identification and characterization of a human DNA glycosylase 
for repair of modified bases in oxidatively damaged DNA", Proc.Natl.Acad.Sci.U.S.A, 
vol. 99, no. 6, pp. 3523-3528. 
Hazra, T. K., Kow, Y. W., Hatahet, Z., Imhoff, B., Boldogh, I., Mokkapati, S. K., Mitra, 
S., & Izumi, T. 2002b, "Identification and characterization of a novel human DNA 
glycosylase for repair of cytosine-derived lesions", Journal of Biological Chemistry, 
vol. 277, no. 34, pp. 30417-30420. 
Hirschhorn, R. 2003, "In vivo reversion to normal of inherited mutations in humans", 
Journal of Medical Genetics, vol. 40, no. 10, pp. 721-728. 
Hirschhorn, R., Yang, D. R., Israni, A., Huie, M. L., & Ownby, D. R. 1994, "Somatic 
mosaicism for a newly identified splice-site mutation in a patient with adenosine 
deaminase-deficient immunodeficiency and spontaneous clinical recovery", American
Journal of Human Genetics, vol. 55, no. 1, pp. 59-68. 
Hirschhorn, R., Yang, D. R., Puck, J. M., Huie, M. L., Jiang, C. K., & Kurlandsky, L. E. 
1996, "Spontaneous in vivo reversion to normal of an inherited mutation in a patient 
with adenosine deaminase deficiency", Nature Genetics, vol. 13, no. 3, pp. 290-295. 
Holme, E. & Lindstedt, S. 1998, "Tyrosinaemia type I and NTBC (2-(2-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione)", J.Inherit.Metab Dis., vol. 21, no. 5, 
pp. 507-517. 
Holme, E. & Lindstedt, S. 2000, "Nontransplant treatment of tyrosinemia", Clin.Liver
Dis., vol. 4, no. 4, pp. 805-814. 
Houdayer, C., Dehainault, C., Mattler, C., Michaux, D., Caux-Moncoutier, V., Pages-
Berhouet, S., d'Enghien, C. D., Lauge, A., Castera, L., Gauthier-Villars, M., & Stoppa-
Lyonnet, D. 2008, "Evaluation of in silico splice tools for decision-making in molecular 
diagnosis", Human Mutation, vol. 29, no. 7, pp. 975-982. 
Iber, F. L., Rosen, H., Levenson, S. M., & Chalmers, T. C. 1957, "The plasma amino 
acids in patients with liver failure", J.Lab Clin.Med., vol. 50, no. 3, pp. 417-425. 
64
Imtiaz, F., Rashed, M. S., Al-Mubarak, B., Allam, R., El-Karaksy, H., Al-Hassnan, Z., 
Al-Owain, M., Al-Zaidan, H., Rahbeeni, Z., Qari, A., Meyer, B. F., & Al-Sayed, M. 
2011, "Identification of mutations causing hereditary tyrosinemia type I in patients of 
Middle Eastern origin", Mol.Genet.Metab. 
Jiang, D., Hatahet, Z., Blaisdell, J. O., Melamede, R. J., & Wallace, S. S. 1997, 
"Escherichia coli endonuclease VIII: cloning, sequencing, and overexpression of the 
nei structural gene and characterization of nei and nei nth mutants", Journal of 
Bacteriology, vol. 179, no. 11, pp. 3773-3782. 
Jonkman, M. F., Scheffer, H., Stulp, R., Pas, H. H., Nijenhuis, M., Heeres, K., 
Owaribe, K., Pulkkinen, L., & Uitto, J. 1997, "Revertant mosaicism in epidermolysis 
bullosa caused by mitotic gene conversion", Cell, vol. 88, no. 4, pp. 543-551. 
Jorquera, R. & Tanguay, R. M. 1997, "The mutagenicity of the tyrosine metabolite, 
fumarylacetoacetate, is enhanced by glutathione depletion", Biochemical and 
Biophysical Research Communications, vol. 232, no. 1, pp. 42-48. 
Katcher, H. L. & Wallace, S. S. 1983, "Characterization of the Escherichia coli X-ray 
endonuclease, endonuclease III", Biochemistry, vol. 22, no. 17, pp. 4071-4081. 
Kim, S. Z., Kupke, K. G., Ierardi-Curto, L., Holme, E., Greter, J., Tanguay, R. M., 
Poudrier, J., D'Astous, M., Lettre, F., Hahn, S. H., & Levy, H. L. 2000, "Hepatocellular 
carcinoma despite long-term survival in chronic tyrosinaemia I", J.Inherit.Metab Dis., 
vol. 23, no. 8, pp. 791-804. 
Klungland, A., Rosewell, I., Hollenbach, S., Larsen, E., Daly, G., Epe, B., Seeberg, 
E., Lindahl, T., & Barnes, D. E. 1999, "Accumulation of premutagenic DNA lesions in 
mice defective in removal of oxidative base damage", Proc.Natl.Acad.Sci.U.S.A, vol. 
96, no. 23, pp. 13300-13305. 
Knox, W. E. 1955, "Enzymes Involved in Conversion of Tyrosine to Acetoacetate", 
Methods in Enzymology, vol. 2, pp. 287-300. 
Krokan, H. E., Otterlei, M., Nilsen, H., Kavli, B., Skorpen, F., Andersen, S., Skjelbred, 
C., Akbari, M., Aas, P. A., & Slupphaug, G. 2001, "Properties and functions of human 
uracil-DNA glycosylase from the UNG gene", Prog.Nucleic Acid Res Mol.Biol., vol. 
68, pp. 365-386. 
Kubo, S., Sun, M., Miyahara, M., Umeyama, K., Urakami, K., Yamamoto, T., Jakobs, 
C., Matsuda, I., & Endo, F. 1998, "Hepatocyte injury in tyrosinemia type 1 is induced 
by fumarylacetoacetate and is inhibited by caspase inhibitors", 
Proc.Natl.Acad.Sci.U.S.A, vol. 95, no. 16, pp. 9552-9557. 
Kume, A., Koremoto, M., Mizukami, H., Okada, T., Hanazono, Y., Sugamura, K., & 
Ozawa, K. 2002, "Selective growth advantage of wild-type lymphocytes in X-linked 
SCID recipients", Bone Marrow Transplantation, vol. 30, no. 2, pp. 113-118. 
Kvittingen, E. A., Halvorsen, S., & Jellum, E. 1983, "Deficient fumarylacetoacetate 
fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary 
tyrosinemia", Pediatric Research, vol. 17, no. 7, pp. 541-544. 
65
Kvittingen, E. A. & Holme, E. 2000, "Disorders of Tyrosine Metabolism," in Inborn 
Metabolic Diseases, 3 edn, J. Fernandes, J. M. Saudubray, & G. van den Berghe, 
eds., Springer-Verlag, Berlin Heidelberg New York, pp. 185-194. 
Kvittingen, E. A., Jellum, E., & Stokke, O. 1981, "Assay of fumarylacetoacetate 
fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia", 
Clinica Chimica Acta, vol. 115, no. 3, pp. 311-319. 
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. 1994, "Self-induced 
correction of the genetic defect in tyrosinemia type I", J.Clin.Invest, vol. 94, no. 4, pp. 
1657-1661. 
Laberge, C. 1969, "Hereditary tyrosinemia in a French Canadian isolate", American
Journal of Human Genetics, vol. 21, no. 1, pp. 36-45. 
Lawley, P. D. 1989, "Mutagens as carcinogens: development of current concepts", 
Mutat.Res, vol. 213, no. 1, pp. 3-25. 
Lehmann, A. R. 2006, "Translesion synthesis in mammalian cells", Exp.Cell Res, vol. 
312, no. 14, pp. 2673-2676. 
Lim, T. H., Fujikane, R., Sano, S., Sakagami, R., Nakatsu, Y., Tsuzuki, T., Sekiguchi, 
M., & Hidaka, M. 2012, "Activation of AMP-activated protein kinase by MAPO1 and 
FLCN induces apoptosis triggered by alkylated base mismatch in DNA", DNA Repair 
(Amst), vol. 11, no. 3, pp. 259-266. 
Lin C. & Knox, W. E. 1958, "Specificity of the adaptive response to tyrosine-alpha-
ketoglutarate transaminase in the rat", Journal of Biological Chemistry, vol. 233, no. 
5, pp. 1186-1189. 
Lindahl, T., Ljungquist, S., Siegert, W., Nyberg, B., & Sperens, B. 1977, "DNA N-
glycosidases: properties of uracil-DNA glycosidase from Escherichia coli", Journal of 
Biological Chemistry, vol. 252, no. 10, pp. 3286-3294. 
Lindblad, B., Fällström, S. P., Höyer, S., Nordborg, C., Solymar, L., & Velander, H. 
1987, "Cardiomyopathy in Fumarylacetoacetase Deficiency (Hereditary 
Tyrosinaemia): a New Feature of the Disease", J.lnher.Metab.Dis., vol. 10, Suppl. 2, 
pp. 319-322. 
Lindblad, B., Lindstedt, S., & Steen, G. 1977, "On the enzymic defects in hereditary 
tyrosinemia", Proc.Natl.Acad.Sci.U.S.A, vol. 74, no. 10, pp. 4641-4645. 
Lindstedt, S., Holme, E., Lock, E. A., Hjalmarson, O., & Strandvik, B. 1992, 
"Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate 
dioxygenase", Lancet, vol. 340, no. 8823, pp. 813-817. 
Liu, Y., Prasad, R., Beard, W. A., Kedar, P. S., Hou, E. W., Shock, D. D., & Wilson, 
S. H. 2007, "Coordination of steps in single-nucleotide base excision repair mediated 
by apurinic/apyrimidinic endonuclease 1 and DNA polymerase beta", Journal of 
Biological Chemistry, vol. 282, no. 18, pp. 13532-13541. 
66
Lo, T. F., Jr., Kwee, M. L., Rooimans, M. A., Oostra, A. B., Veerman, A. J., van, W. 
M., Pauli, R. M., Shahidi, N. T., Dokal, I., Roberts, I., Altay, C., Gluckman, E., Gibson, 
R. A., Mathew, C. G., Arwert, F., & Joenje, H. 1997, "Somatic mosaicism in Fanconi 
anemia: molecular basis and clinical significance", European Journal of Human 
Genetics, vol. 5, no. 3, pp. 137-148. 
Lovell, M. A. & Markesbery, W. R. 2007, "Oxidative DNA damage in mild cognitive 
impairment and late-stage Alzheimer's disease", Nucleic Acids Res, vol. 35, no. 22, 
pp. 7497-7504. 
Mahuran, D. J., Angus, R. H., Braun, C. V., Sim, S. S., & Schmidt, D. E., Jr. 1977, 
"Characterization and substrate specificity of fumarylacetoacetate fumarylhydrolase", 
Canadian Journal of Biochemistry, vol. 55, no. 1, pp. 1-8. 
Manabe, S., Sassa, S., & Kappas, A. 1985, "Hereditary tyrosinemia. Formation of 
succinylacetone-amino acid adducts", Journal of Experimental Medicine, vol. 162, no. 
3, pp. 1060-1074. 
Manning, K., Al Dhalimy, M., Finegold, M., & Grompe, M. 1999, "In vivo suppressor 
mutations correct a murine model of hereditary tyrosinemia type I", 
Proc.Natl.Acad.Sci.U.S.A, vol. 96, no. 21, pp. 11928-11933. 
Michaels, M. L. & Miller, J. H. 1992, "The GO system protects organisms from the 
mutagenic effect of the spontaneous lesion 8-hydroxyguanine (7,8-dihydro-8-
oxoguanine)", Journal of Bacteriology, vol. 174, no. 20, pp. 6321-6325. 
Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, 
M., Lacroix, J., Vanasse, M., Larbrisseau, A., & . 1990, "Neurologic crises in 
hereditary tyrosinemia", New England Journal of Medicine, vol. 322, no. 7, pp. 432-
437. 
Mitchell, G. A., Grompe, M., Lambert, M., & Tanguay, R. M. 2001, 
"Hypertyrosinemia," in The meatbolic & Molecular Bases of Inherited Disease., C. R. 
Scriver et al., eds., McGraw-Hill, New York, pp. 1777-1805. 
Morland, I., Luna, L., Gustad, E., Seeberg, E., & Bjoras, M. 2005, "Product inhibition 
and magnesium modulate the dual reaction mode of hOgg1", DNA Repair (Amst), 
vol. 4, no. 3, pp. 381-387. 
Morland, I., Rolseth, V., Luna, L., Rognes, T., Bjoras, M., & Seeberg, E. 2002, 
"Human DNA glycosylases of the bacterial Fpg/MutM superfamily: an alternative 
pathway for the repair of 8-oxoguanine and other oxidation products in DNA", Nucleic
Acids Res, vol. 30, no. 22, pp. 4926-4936. 
Nakabeppu, Y., Kajitani, K., Sakamoto, K., Yamaguchi, H., & Tsuchimoto, D. 2006, 
"MTH1, an oxidized purine nucleoside triphosphatase, prevents the cytotoxicity and 
neurotoxicity of oxidized purine nucleotides", DNA Repair (Amst), vol. 5, no. 7, pp. 
761-772. 
Nilsen, H., Stamp, G., Andersen, S., Hrivnak, G., Krokan, H. E., Lindahl, T., & 
Barnes, D. E. 2003, "Gene-targeted mice lacking the Ung uracil-DNA glycosylase 
develop B-cell lymphomas", Oncogene, vol. 22, no. 35, pp. 5381-5386. 
67
Nishioka, K., Ohtsubo, T., Oda, H., Fujiwara, T., Kang, D., Sugimachi, K., & 
Nakabeppu, Y. 1999, "Expression and differential intracellular localization of two 
major forms of human 8-oxoguanine DNA glycosylase encoded by alternatively 
spliced OGG1 mRNAs", Molecular Biology of the Cell, vol. 10, no. 5, pp. 1637-1652. 
O'Driscoll, M. & Jeggo, P. A. 2006, "The role of double-strand break repair - insights 
from human genetics", Nat.Rev.Genet., vol. 7, no. 1, pp. 45-54. 
Ohisalo, J. J., Laskowska-Klita, T., & Andersson, S. M. 1982, "Development of 
tyrosine aminotransferase and para-hydroxyphenylpyruvate dioxygenase activities in 
fetal and neonatal human liver", J.Clin.Invest, vol. 70, no. 1, pp. 198-200. 
Orejuela, D., Jorquera, R., Bergeron, A., Finegold, M. J., & Tanguay, R. M. 2008, 
"Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival 
pathway in the fah-/- knockout mice model", Journal of Hepatology, vol. 48, no. 2, pp. 
308-317. 
Osterod, M., Hollenbach, S., Hengstler, J. G., Barnes, D. E., Lindahl, T., & Epe, B. 
2001, "Age-related and tissue-specific accumulation of oxidative DNA base damage 
in 7,8-dihydro-8-oxoguanine-DNA glycosylase (Ogg1) deficient mice", 
Carcinogenesis, vol. 22, no. 9, pp. 1459-1463. 
Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C. N., Finegold, M., & 
Grompe, M. 1996, "Hepatocytes corrected by gene therapy are selected in vivo in a 
murine model of hereditary tyrosinaemia type I", Nature Genetics, vol. 12, no. 3, pp. 
266-273. 
Paradis, K., Weber, A., Seidman, E. G., Larochelle, J., Garel, L., Lenaerts, C., & Roy, 
C. C. 1990, "Liver transplantation for hereditary tyrosinemia: the Quebec experience", 
American Journal of Human Genetics, vol. 47, no. 2, pp. 338-342. 
Pasmooij, A. M., Pas, H. H., Bolling, M. C., & Jonkman, M. F. 2007, "Revertant 
mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site 
mutations in LAMB3", J.Clin.Invest, vol. 117, no. 5, pp. 1240-1248. 
Pasmooij, A. M., Pas, H. H., Deviaene, F. C., Nijenhuis, M., & Jonkman, M. F. 2005, 
"Multiple correcting COL17A1 mutations in patients with revertant mosaicism of 
epidermolysis bullosa", American Journal of Human Genetics, vol. 77, no. 5, pp. 727-
740. 
Poudrier, J., Lettre, F., Scriver, C. R., Larochelle, J., & Tanguay, R. M. 1998, 
"Different clinical forms of hereditary tyrosinemia (type I) in patients with identical 
genotypes", Mol.Genet.Metab, vol. 64, no. 2, pp. 119-125. 
Prieto-Alamo, M. J. & Laval, F. 1998, "Deficient DNA-ligase activity in the metabolic 
disease tyrosinemia type I", Proc.Natl.Acad.Sci.U.S.A, vol. 95, no. 21, pp. 12614-
12618. 
Radman, M. 1976, "An endonuclease from Escherichia coli that introduces single 
polynucleotide chain scissions in ultraviolet-irradiated DNA", Journal of Biological 
Chemistry, vol. 251, no. 5, pp. 1438-1445. 
68
Rootwelt, H., Berger, R., Gray, G., Kelly, D. A., Coskun, T., & Kvittingen, E. A. 1994, 
"Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene 
causing tyrosinemia type 1", American Journal of Human Genetics, vol. 55, no. 4, pp. 
653-658. 
Rootwelt, H., Brodtkorb, E., & Kvittingen, E. A. 1994, "Identification of a frequent 
pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for 
diagnosis of tyrosinemia type I", American Journal of Human Genetics, vol. 55, no. 6, 
pp. 1122-1127. 
Rootwelt, H., Hoie, K., Berger, R., & Kvittingen, E. A. 1996, "Fumarylacetoacetase 
mutations in tyrosinaemia type I", Human Mutation, vol. 7, no. 3, pp. 239-243. 
Rosenquist, T. A., Zaika, E., Fernandes, A. S., Zharkov, D. O., Miller, H., & Grollman, 
A. P. 2003, "The novel DNA glycosylase, NEIL1, protects mammalian cells from 
radiation-mediated cell death", DNA Repair (Amst), vol. 2, no. 5, pp. 581-591. 
Russell, L. B., Russell, W. L., & Kelly, E. M. 1979, "Analysis of the albino-locus region 
of the mouse. I. Origin and viability", Genetics, vol. 91, no. 1, pp. 127-139. 
Saito, Y., Uraki, F., Nakajima, S., Asaeda, A., Ono, K., Kubo, K., & Yamamoto, K. 
1997, "Characterization of endonuclease III (nth) and endonuclease VIII (nei) 
mutants of Escherichia coli K-12", Journal of Bacteriology, vol. 179, no. 11, pp. 3783-
3785. 
Sampath, H., Batra, A. K., Vartanian, V., Carmical, J. R., Prusak, D., King, I. B., 
Lowell, B., Earley, L. F., Wood, T. G., Marks, D. L., McCullough, A. K., & Stephen, R. 
2011, "Variable penetrance of metabolic phenotypes and development of high-fat 
diet-induced adiposity in NEIL1-deficient mice", Am.J.Physiol Endocrinol.Metab, vol. 
300, no. 4, p. E724-E734. 
Santra, S., Preece, M. A., Hulton, S. A., & McKiernan, P. J. 2008, "Renal tubular 
function in children with tyrosinaemia type I treated with nitisinone", J.Inherit.Metab
Dis., vol. 31, no. 3, pp. 399-402. 
Schuilenga-Hut, P. H., Scheffer, H., Pas, H. H., Nijenhuis, M., Buys, C. H., & 
Jonkman, M. F. 2002, "Partial revertant mosaicism of keratin 14 in a patient with 
recessive epidermolysis bullosa simplex", J.Invest Dermatol., vol. 118, no. 4, pp. 626-
630. 
Scriver, C. R. 2006, "Community genetics and dignity in diversity in the Quebec 
Network of Genetic Medicine", Community Genet., vol. 9, no. 3, pp. 142-152. 
Scriver, C. R. 2008, "Garrod's Croonian Lectures (1908) and the charter 'Inborn 
Errors of Metabolism': albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 
2008", J.Inherit.Metab Dis., vol. 31, no. 5, pp. 580-598. 
Scriver, C. R. & Rosenberg, L. E. 1973, "Amino acid metabolism and its disorders", 
Major.Probl.Clin.Pediatr, vol. 10, pp. 1-478. 
Seeberg, E. & Fuchs, R. P. 1990, "Acetylaminofluorene bound to different guanines 
of the sequence -GG", Proc.Natl.Acad.Sci.U.S.A, vol. 87, no. 1, pp. 191-194. 
69
Sejersted, Y., Hildrestrand, G. A., Kunke, D., Rolseth, V., Krokeide, S. Z., Neurauter, 
C. G., Suganthan, R., tneosen-Asegg, M., Fleming, A. M., Saugstad, O. D., Burrows, 
C. J., Luna, L., & Bjoras, M. 2011, "Endonuclease VIII-like 3 (Neil3) DNA glycosylase 
promotes neurogenesis induced by hypoxia-ischemia", Proc.Natl.Acad.Sci.U.S.A, 
vol. 108, no. 46, pp. 18802-18807. 
Sgaravatti, A. M., Magnusson, A. S., de Oliveira, A. S., Rosa, A. P., Mescka, C. P., 
Zanin, F. R., Pederzolli, C. D., Wyse, A. T., Wannmacher, C. M., Wajner, M., & 
Dutra-Filho, C. S. 2009, "Tyrosine administration decreases glutathione and 
stimulates lipid and protein oxidation in rat cerebral cortex", Metab Brain Dis., vol. 24, 
no. 3, pp. 415-425. 
Shibutani, S., Takeshita, M., & Grollman, A. P. 1991, "Insertion of specific bases 
during DNA synthesis past the oxidation-damaged base 8-oxodG", Nature, vol. 349, 
no. 6308, pp. 431-434. 
Slupska, M. M., Baikalov, C., Luther, W. M., Chiang, J. H., Wei, Y. F., & Miller, J. H. 
1996, "Cloning and sequencing a human homolog (hMYH) of the Escherichia coli 
mutY gene whose function is required for the repair of oxidative DNA damage", 
Journal of Bacteriology, vol. 178, no. 13, pp. 3885-3892. 
Spencer, P. D., Medow, M. S., Moses, L. C., & Roth, K. S. 1988, "Effects of 
succinylacetone on the uptake of sugars and amino acids by brush border vesicles", 
Kidney International, vol. 34, no. 5, pp. 671-677. 
Spencer, P. D. & Roth, K. S. 1987, "Effects of succinylacetone on amino acid uptake 
in the rat kidney", Biochem.Med.Metab Biol., vol. 37, no. 1, pp. 101-109. 
Stenson et al (2009). The Human Gene Mutation Database (HGMD®). 
Curr.Protoc.Bioinformatics. Chapter 1, Unit. 2011.  
Ref Type: Electronic Citation 
Strniste, G. F. & Wallace, S. S. 1975, "Endonucleolytic incision of x-irradiated 
deoxyribonucleic acid by extracts of Escherichia coli", Proc.Natl.Acad.Sci.U.S.A, vol. 
72, no. 6, pp. 1997-2001. 
Sun, M. S., Hattori, S., Kubo, S., Awata, H., Matsuda, I., & Endo, F. 2000, "A mouse 
model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi 
syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice", 
Journal of the American Society of Nephrology, vol. 11, no. 2, pp. 291-300. 
Takao, M., Kanno, S., Kobayashi, K., Zhang, Q. M., Yonei, S., van der Horst, G. T., & 
Yasui, A. 2002, "A back-up glycosylase in Nth1 knock-out mice is a functional Nei 
(endonuclease VIII) homologue", Journal of Biological Chemistry, vol. 277, no. 44, 
pp. 42205-42213. 
Takao, M., Zhang, Q. M., Yonei, S., & Yasui, A. 1999, "Differential subcellular 
localization of human MutY homolog (hMYH) and the functional activity of adenine:8-
oxoguanine DNA glycosylase", Nucleic Acids Res, vol. 27, no. 18, pp. 3638-3644. 
70
Tschudy, D. P., Hess, R. A., Frykholm, B. C., & Blaese, R. M. 1982, 
"Immunosuppressive activity of succinylacetone", J.Lab Clin.Med., vol. 99, no. 4, pp. 
526-532. 
van der Kemp, P. A., Thomas, D., Barbey, R., de, O. R., & Boiteux, S. 1996, "Cloning 
and expression in Escherichia coli of the OGG1 gene of Saccharomyces cerevisiae, 
which codes for a DNA glycosylase that excises 7,8-dihydro-8-oxoguanine and 2,6-
diamino-4-hydroxy-5-N-methylformamidopyrimidine", Proc.Natl.Acad.Sci.U.S.A, vol. 
93, no. 11, pp. 5197-5202. 
van Dyk E. & Pretorius, P. J. 2011, "Impaired DNA repair and genomic stability in 
hereditary tyrosinemia type 1", Gene. 
van Dyk, E., Steenkamp, A., Koekemoer, G., & Pretorius, P. J. 2010, "Hereditary 
tyrosinemia type 1 metabolites impair DNA excision repair pathways", Biochemical
and Biophysical Research Communications, vol. 401, no. 1, pp. 32-36. 
van Spronsen, F. J., Thomasse, Y., Smit, G. P., Leonard, J. V., Clayton, P. T., Fidler, 
V., Berger, R., & Heymans, H. S. 1994, "Hereditary tyrosinemia type I: a new clinical 
classification with difference in prognosis on dietary treatment", Hepatology, vol. 20, 
no. 5, pp. 1187-1191. 
Van, F. H., van, d. B., I, & Berger, R. 1990, "Purification of human liver 
fumarylacetoacetase using immunoaffinity chromatography", Journal of Biochemical 
and Biophysical Methods, vol. 20, no. 4, pp. 317-324. 
Vogel, A., van, d. B., I, Al-Dhalimy, M., Groopman, J., Ou, C. N., Ryabinina, O., 
Iordanov, M. S., Finegold, M., & Grompe, M. 2004, "Chronic liver disease in murine 
hereditary tyrosinemia type 1 induces resistance to cell death", Hepatology, vol. 39, 
no. 2, pp. 433-443. 
Waisfisz, Q., Morgan, N. V., Savino, M., de Winter, J. P., van Berkel, C. G., Hoatlin, 
M. E., Ianzano, L., Gibson, R. A., Arwert, F., Savoia, A., Mathew, C. G., Pronk, J. C., 
& Joenje, H. 1999, "Spontaneous functional correction of homozygous fanconi 
anaemia alleles reveals novel mechanistic basis for reverse mosaicism", Nature
Genetics, vol. 22, no. 4, pp. 379-383. 
Willis, A. E. & Lindahl, T. 1987, "DNA ligase I deficiency in Bloom's syndrome", 
Nature, vol. 325, no. 6102, pp. 355-357. 
Wilson, K. S., Timmons, C. F., Hilton, D. S., Weinberg, A. G., & Tonk, V. 1994, 
"Chromosomal instability in hereditary tyrosinemia type I", Pediatr Pathol., vol. 14, no. 
6, pp. 1055-1057. 
Xie, Y., Yang, H., Cunanan, C., Okamoto, K., Shibata, D., Pan, J., Barnes, D. E., 
Lindahl, T., McIlhatton, M., Fishel, R., & Miller, J. H. 2004, "Deficiencies in mouse 
Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the 
K-ras oncogene in lung tumors", Cancer Res, vol. 64, no. 9, pp. 3096-3102. 
Yang, T. P., Stout, J. T., Konecki, D. S., Patel, P. I., Alford, R. L., & Caskey, C. T. 
1988, "Spontaneous reversion of novel Lesch-Nyhan mutation by HPRT gene 
rearrangement", Somatic Cell and Molecular Genetics, vol. 14, no. 3, pp. 293-303. 
71
Yeo, G. & Burge, C. B. 2004, "Maximum entropy modeling of short sequence motifs 
with applications to RNA splicing signals", Journal of Computational Biology, vol. 11, 
no. 2-3, pp. 377-394. 
 
 
72
Errata
Page 13, step 2:
“This enzyme is dependent on Cu,” should be: “This enzyme is dependent on ferrous 
iron, “ 
“The enzyme is inhibited by the metabolite fumarylacetoacetate (FAA),” should be: 
“The enzyme is deficient in tyrosinaemia patiens as a secondary phenomenon to the 
primary enzyme defect,” 
Page 13, step 4: 
“This enzyme requires reduced glutathione probably in order to maintain its sulfhydryl 
groups in reduced form.” should be: “This enzyme is a  glutathione-S-transferase 
(glutathione-S-transferase, Zeta 1) and requires reduced glutathione.” 
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Abstract
28 Norwegians have been diagnosed with hereditary tyrosinaemia type I (HT1) over the last 30 
years. In this study, 19 of these patients were investigated. Three novel small deletions were found 
(NM_000137.1(FAH): c.615delT, p.Phe205LeufsX2, NM_000137.1(FAH): c.744delG, 
p.Pro249HisfsX55 and NM_000137.1(FAH):c835delC) pGln279ArgfsX25, all of them leading to 
a change in the reading frame and a premature stop codon. 51 of the 56 disease causing alleles are 
hereby genetically characterized, identifying 9 different disease causing mutations in the 
Norwegian population. 65 % of the Norwegian HT1 patients are compound heterozygous for 
different mutations. Thus, the relatively high incidence of HT1 in Norway of 1 in 74,800 live 
births is not due to single founder effects or high incidence of parental consanguinity.
Key words:
Inborn Errors of Metabolism, Metabolic Disease, Single Gene Disorders, Amino Acids, 
Epidemiology, Genotype, Frameshift Mutation, Liver Disease, Hepatocellular carcinoma 
Background
Hereditary tyrosinaemia type I [(HT1) MIM 276700] is an autosomal recessive disorder caused by 
deficiency of fumarylacetoacetase [(FAH) E.C. 3.7.1.2], the last enzyme in the tyrosine 
degradation pathway, which leads to accumulation of the pathogenic metabolites 
fumarylacetoacetate (FAA) and maleylacetoacetate (MAA) and their derivatives 
succinylacetoacetate and succinylacetone. FAA and MAA are alkylating agents and form 
glutathione adducts that are assumed to cause the organ damage symptomatic of the disorder. HT1 
is a disease with highly variable clinical symptoms with onset occurring between infancy and 
adolescence. It is characterized by progressive liver disease and secondary renal tubular 
dysfunction. In the most acute form the patients present with severe liver failure within weeks of 
birth, whereas hypophosphatemic rickets may be the first symptom in chronic HT1. Untreated 
HT1 patients die from liver cirrhosis or hepatocellular carcinoma at a young age. The treatment 
consists of a protein restricted diet, and the drug NTBC (Orfadine®) which inhibits the breakdown 
of tyrosine and thus the production of the toxic metabolites. The drug has dramatically improved 
the prognosis. [1].The human FAH gene (FAH) is located on chromosome 15q23-q25, spans 30-
35 kb and consists of 14 exons. The cDNA has an open reading frame of 1257 bp encoding 419 
amino acids [2;3]. 55 disease causing mutations are registered in the HGMD Professional database 
(Human Gene Mutation Database; release date December 9th, 2011) [4]. In addition, 11 new 
mutations of Middle Eastern origin were recently reported [5]. The missense mutation Q279R 
reported previously [6] is not in the HGMD database. Three of the total of 67 mutations are small 
deletions. HT1 is a rare disease, but the incidence is extraordinarily high (1 in 16,700 live births) 
in the province of Quebec in Canada due to a founder mutation [7]. The incidence in the rest of 
world, including Scandinavia, has previously been estimated to be 1 in 100-120,000[1]. Before 
this study 6 different disease causing mutations had been found in Norwegian patients [8]. 
Materials and methods 
Patients
During the last three decades 28 Norwegian HT1 patients (17 males and 11 females) have been 
diagnosed with HT1 in our laboratory (The Norwegian National Laboratory of Inborn Errors of 
Metabolism, Department of Medical Biochemistry, Oslo University Hospital.) No DNA material 
is available for 2 patients. 7 patients have previously been investigated and fully characterized. [8] 
Three additional patients in the same study were not fully characterized, since only one of the 
mutated alleles was identified in each of them. In this study the latter three patients and 16 new 
patients are investigated. DNA from leukocytes or fibroblasts was used from all patients. From 
one of the three partly characterized patients, DNA material was unavailable. Since the patient’s 
paternal mutation was known, maternal DNA was used for further analyses. DNA from 100 
control individuals (200 alleles) was used to exclude polymorphisms. 
Sequencing and Restriction enzyme analyses: 
PCR products from three of the HT1-patients with one or two unknown mutations and from the 
mother of one patient were generated. The products from all 14 exons of FAH, including 28-101 
intronic bp of the exon-intron boundaries, were subjected to sequencing. The primers used are 
listed in table I. Sequence analysis was performed after treatment with ExoSAP-IT® (Affymetrix 
Inc. Santa Clara, California 95051, USA) using Big Dye® Terminator v3.1 Cycle Sequencing Kit 
and an automated ABI 3100 or 3730 auto sequencer (Applied Biosystems, CA, USA). The novel 
mutations (c.615delT, c.744delG and c.835delC) were confirmed by PCR amplification and 
restriction enzyme digestion. The enzymes and primers used are listed in table II (mismatch bases 
are underlined). Other mutations (IVS12+5G>A , G337S, E357X) in FAH were detected by 
restriction enzyme analyses as reported previously[8]. The rest of the patients were investigated by 
restriction enzyme analyses only. 
Protein structure 
The consequences of the novel mutations were analyzed with PYMOL (http://www.pymol.org), 
using the experimentally determined structure of mouse FAH [9]. 
Statistics for calculating the incidence of HT1 in Norway. 
The treatment with NTBC is likely to have increased the awareness of HT1. Thus the year of the 
first trial of NTBC, 1991 [10], was chosen as the starting point for calculating the incidence of 
HT1 in Norway. December 31st, 2010 was chosen as end point of the interval. 14 patients born in 
this period were diagnosed in our laboratory, which is the only one in Norway offering a selective 
metabolic screening. A point estimate of the undiagnosed patients was made based on our 
patients’ ages at the time of diagnosis. Additionally we have diagnosed one patient after December 
31st, 2010. Of this total of 15 patients, 5 were found as a result of an already diagnosed sibling and 
not because of symptoms, leaving 10 as index patients with ages at time of diagnosis equal to 
0.055, 0.214, 0.386, 0.430, 1.158, 1.478, 1.739, 2.209, 4.652, and 7.337 years. This age 
distribution was made normal by means of the Box-Cox transformation with parameter  = 
0.1775, which yielded  = 0.0807,  = 1.4293, and skewness virtually zero. The number (nj) and 
average age (aj) of individuals in each monthly cohort were calculated from annual data of live 
births in Norway from January 1991 to December 2010. Incidence, f, was assumed to be 
unchanged over this period. The same Box-Cox transformation was applied to all aj. Transformed 
ages were denoted i. The number of diagnosed individuals in the period should be equal to 
f·  = 14. Pj is the area under the standard normal distribution up to the z-scorej
j
j Pn 

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In this expression all values for nj are known from the birth registry, and each 
Pj can be calculated from the standard normal distribution, given i, , and . Summing up this 
gives f· 1047079.3 = 14. Hence f = 1.33705E-05, and the number of expected undiagnosed 
individuals is f· = f· 134556.7 = 1.80. )1(
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Ethics
For all living individuals contributing biological material, written, informed consent has been 
obtained. Dispensation was given by “The Norwegian Directorate of Health” for the deceased 
HT1-patients. The study was approved by the regional committee for medical research ethics. 
Results
Sequencing FAH from the HT1 patients identified 3 novel, small deletions; F205LfsX2 
(NM_000137.1(FAH):c.615delT, p.Phe205LeufsX2), P249HfsX55 
(NM_000137.1(FAH):c.744delG, p. Pro249HisfsX55) and Q279RfsX25 
(NM_000137.1(FAH):c835delC, pGln279ArgfsX25). All three mutations were confirmed by  
restriction enzyme analyses (figure 1). The novel mutations lead to frame shift and premature 
termination codons. F205LfsX2 changes the next triplet to a premature stop codon (TAG). Both 
P249HfsX55 and Q279RfsX25 lead to a premature stop codon (TGA) towards the end of exon 10. 
None of the three novel deletions were found in the 200 control alleles. F205LfsX2 was found in 
one patient who was compound heterozygous with the missense mutation G337S. P249HfsX55 
was found in 5 patients (7 alleles), 2 were homozygous, 2 were compound heterozygous with the 
intron 12 splice site mutation IVS12+5G>A (NM_000137.1(FAH):c.1062+5G>A), and one 
patient was compound heterozygous with the nonsense mutation W262X. Q279RfsX25 was found 
in 2 patients. Both were compound heterozygous with the missense mutation G337S. 
 1,181,636 children have been born in Norway between January 1st,1991 and December 
31st, 2010 [11]. 15.8 patients (14 diagnosed and 1.8 undiagnosed) suggest an incidence of 1 in 
74,800 live births. 
Discussion
The three novel mutations in FAH result in premature stop codons with probable deleterious 
effects on enzyme function. Figure 2 shows the structure of the murine FAH protein and the 
predicted consequences of the mutations P249HfsX55 (A), F205LfsX2 (B) and Q279RfsX25 (C). 
In all cases large parts of the FAH protein are affected and normal folding, function and stability 
of the protein can not be expected. Although this is a murine protein structure, the same can be 
expected for the human protein, for which no structure is available, since there is a high degree of 
homology between the murine and the human protein. 372 of 419 amino acids (89 %) are identical 
(fig. 2D)  [12]. A mismatch mutation generating Q279R has previously been reported as a disease 
causing mutation[6], further supporting the Q279RfsX25 deletion mutation as a causal mutation. 
In addition to a detrimental effect on the enzyme function, premature termination codons 
frequently result in mRNA degradation through nonsense-mediated mRNA decay when they occur 
more than 50 nucleotides 5´ to the terminal exon-exon junction, as they do with these three 
mutations  [13]. This drastically reduces the amount of expressed protein in vivo.
51 of 52 alleles from the Norwegian HT1 patients with available DNA material are now 
characterized in this and previous studies[8], identifying 9 different FAH mutations in the 
Norwegian HT1 population (figure 3). IVS12+5G>A is the most common, found in 40.4 % of the 
alleles. P249HfsX55, Q279RfsX25 and F205LfsX2 are found in 13.5 %, 3.8 % and 1.9 % of the 
alleles, respectively. A single mutated allele was found in one patient despite a classical clinical 
and biochemical phenotype. The second mutation may be located outside the regions analyzed, 
affecting FAH transcription, splicing or mRNA stability. It could also be principally due to a germ 
cell mutation in the mother or an early de novo mutation in the patient that would not appear in the 
FAH of the mother’s fibroblasts, which we have investigated in this particular case. 9 patients are 
homozygous; 4 for IVS12+5G>A, 3 for G337S and 2 for P249HfsX55. The remaining 17 (65 %) 
of the 26 Norwegian patients with available DNA-material are compound heterozygous for 
different mutations, demonstrating the lack of major founder effects and parental consanguinity.
This work gives the best possible estimate of the incidence of HT1 in the Norwegian 
population. Our laboratory is the only laboratory in Norway performing selective metabolic 
screening, and to our knowledge there are no other patients in Norway with a HT1 diagnosis made 
elsewhere. Newborn screening has not included HT1 in Norway. Furthermore, some cases of HT1 
may also have been missed due to death by liver failure or hepatocellular carcinoma prior to or 
without the appropriate analyses being performed. This work shows that the incidence of HT1 in 
Norway is among the highest reported. The incidence in the Middle East is also proclaimed to be 
higher than average, but no number is given [5]. The high incidences in the Quebec region of 
Canada and the Middle East are due to a founder mutation and consanguineous mating, 
respectively. In Norway, however, the high incidence is caused by a high number (at least 9) of 
different disease causing FAH mutations in a relatively small population.
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Table I, PCR and Sequencing primers
Exon (FAH) PCR primer, sense PCR primer, antisense Sequencing primer 
1 GGGTGTTCACGGTGAGACCAA CATTCCACTCCATTCCACTCCA CTCCGCACGCCACCTTAG 
2 GGGGGACCTGTGGACTCTTC TCGGAAATGGAACGCAAGGA CTTTCTGAGTAAATGAGCCA 
3 AAGAGCAGAGGTCCTGAGAGTTT AGAATGGCACTGATAACCACA TCCATTGGAAGGAGGGATAC 
4 AGGTGCCCACTGGAGATTGT GCCTGGATGCTGGGAAAGGTC  GGGCTGAGCCCGTGGGTGGG 
5 GGCTGAGCTCTGGATGTGTA GACATTTGGCCCAGTTCATA GTGCTTGGAACAGTCCATTC 
6 + 7 TAACAGCTCTGATGCCCTGCATTC GCTGAAGAGGAGGGGAGTG  GACAACATATAACAGCTCTG 
8 TCTGCTTTCCTGAGGCGTCCAT TGAGTGGCCCGAGTTCTTAGAG  TCTCTAGGTGACAAGTGACC 
9 TGGAGATGGCAGTGCTAGGT GGCTGCCTGGAAGTAATCGT GTTGGGAGATGCCCTGATCA
10 GGTTTGGCTCCTGTGACCTT AGCTCCTGGCCATGTCAGTC  GCTCAGCCCACCTGCCAGTG 
11 CCTCCCTGATGCATGGAATT TCTCTCTTTCCCTCAATTCT TTTTCCTCCCTGATGCATGG 
12 AGCAGAGGAGCTGAGGTTGGA TGCACCCAGAGAGAAAGGCTA GCCTCCGGGATGCTAGGCTA 
13 TCGGGACTCCCAGGTCTTGCT CCGCAGCTAGAACAGTGCAT CATGGTCCATGCCAGAGCCCAAAGG 
14 CGCTGCCTAGGTGTTGGTT CACTGAATAGCGGACCAG GTGTTGGTTCCGGTGAGCCC 
Table II Restriction enzyme analyses
Mutation Restriction enzyme Sense primer Antisense primer 
P249HfsX55 ApaI GTTGGGAGATGCCCTGATCA  TCCCAAAACTCTTCCCAAGGAAGGG
F205LfsX2 Mwo I GTGACCTGGGCGGCAGAT CTCTCCCAATCTGTTTCCAGGGCCTGCA
Q279RfsX25 Mbo II  TGGAGATGGCAGTGCTAGGT GGCTGCCTGGAAGTAATCGT 
Figure 1 
A: Sequencing of exon 9 of FAH. The yellow frame shows the small deletion c.744delG. 
B: Verification of the mutation Pro249HisfsX55 by restriction enzyme digestion of a 119 bp PCR 
product. The mutated allele remains undigested, whereas the normal allele is digested into 
fragments of 96 and 23 bp. Lane 1: DNA Molecular Weight Marker V (Roche Applied Science) 
Lane 2: Undigested PCR product. Lane 3: Homozygous sample. Lane 4: Heterozygous sample. 
Lane 5: Negative control.
C: Sequencing of exon 8 of FAH. The yellow frame shows the small deletion c.615delT. 
D: Analyses of the mutation Phe205LeufsX2 by restriction enzyme digestion of a 90 bp PCR 
product. The mutated allele remains undigested, and the normal allele is digested into fragments of 
61 and 29 bp. Lane 1: DNA Molecular Weight Marker V Lane 2: Undigested PCR product. Lane 
3: Heterozygous sample. Lane 4: Negative control. 
E: Sequencing of exon 9 of FAH. The yellow frame shows the small deletion c.835delC. 
F: Analyses of the mutation pGln279ArgfsX25 by restriction enzyme digestion of a 415 bp PCR 
product. The normal allele contains 2 restriction sites. The digested normal allele consists of 
fragments of 243, 92 and 80 bp. The deletion c.835delc introduces a third restriction site, thus the 
digested mutated allele consists of fragments of 167, 92, 80 and 76 bp. Lane 1: DNA Molecular 
Weight Marker V Lane 2: Undigested PCR product. Lane 3: Negative control. Lane 4: 
Heterozygous sample. 
* 123 and 124 bp. ** 267 bp. *** 434 and 458 bp. 
Figure 2 
A, B and C: The three-dimensional structure of the murine FAH protein (PDB id: 1HYO) and the 
predicted consequences of the mutations P249HfsX55 (A), F205LfsX2 (B) and Q279RfsX25 (C). 
The arrows point to the mutated site. The resulting changes in the amino acid sequence are 
coloured orange. The parts of the protein downstream of the termination codon are coloured grey. 
D: Amino acid sequence alignment of the human and the murine FAH protein showing that 372 of 
419 amino acids (89 %) are identical (blue colour). 
Figure 3 
FAH with the location of the 9 disease causing mutations found among Norwegian patients. The 
rectangles represent the 14 exons separated by 13 introns. F205LfsX2, P249HfsX55 and 
Q279RfsX25 are novel mutations. The frequency of each mutation in the Norwegian HT1 
population is indicated. 
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Abstract
 
Hereditary tyrosinaemia type 1 (HT1) is an autosomal recessive disease caused by a 
deficiency in the human fumarylacetoacetate hydrolase (FAH), which is the last enzyme in the 
catabolic pathway of tyrosine. Several reports suggest that intracellular accumulation of 
intermediates of tyrosine catabolism such as fumarylacetoacetate (FAA) and succinylacetone 
(SA) is important for the pathogenesis in liver and kidney of HT1 patients. In this work we 
examined the effect of FAA and SA on DNA glycosylases initiating base excision repair 
(BER), which is the most important pathway for removing mutagenic DNA base lesions. In 
vitro assays monitoring DNA glycosylase activity of Ogg1, Neil1 and Neil2 demonstrated that 
FAA but not SA inhibited base removal strongly. These DNA glycosylases initiate excision of 
a broad range of mutagenic oxidative base lesions. Further, FAA and SA showed no 
inhibitory effect on the activity of uracil DNA glycosylase, Ung2. These data indicate that 
inhibition of DNA glycosylases oxidative base lesions by FAA in HT1 patients increase 
mutagenesis, suggesting an important mechanism for development of hepatocarcinoma and 
somatic mosaicism.    . 
Introduction 
Hereditary tyrosinaemia type I [(HT1) MIM 276700] is a disease of autosomal recessive 
inheritance. It is caused by deficiency of fumarylacetoacetase [(FAH) E.C. 3.7.1.2],  the last 
enzyme of tyrosine degradation. The condition leads to accumulation of the metabolites 
fumarylacetoacetate (FAA) and succinylacetone (SA), Fig.1A. HT1 is characterized by 
hypophosphatemic rickets due to renal tubular dysfunction and progressive liver disease with 
pronounced regeneration (Mitchell et al. 2001). The assumption of increased mutagenesis in 
hepatocytes of HT1 patients is supported by the high incidence of hepatocellular carcinoma, 
and by the frequent phenomenon of point mutation reversion in liver nodules (Bliksrud et al. 
2005). FAA contribute to genomic instability in HT1 hepatocytes being an alkylating agent 
and by generating glutathione adducts leading to increased oxidative stress (Jorquera and 
Tanguay 1997). Less is known about the effect of FAA and SA on DNA repair enzymes such 
as DNA glycosylases that recognize and initiate repair of numerous mutagenic base lesions in 
the genome.  
Base excision repair (BER) is the most important pathway for repair of DNA base 
damage, abasic sites and single strand breaks. The BER pathway is initiated by a DNA 
glycosylase removing the damaged base, Fig. 1B (I). The resulting abasic site is further 
processed by an AP-lyase activity associated with bifunctional DNA glycoslyases or by an 
AP-endonuclase, Fig. 1B (II). The suger-phosphate residue at the nicked abasic site is 
removed by 5’ or 3’ phosphodiesterase activities and repair synthesis is completed by DNA 
polymerase and DNA ligase, Fig. 1B (III). DNA-glycosylases are classified as mono or 
bifunctional based on their reaction mechanism. The monofunctional DNA glycosylases 
attack the N-glycosylic bond at C1 carbon of sugar, creating a free base and an intact abasic 
site. The bifunctional DNA glycosylases are associated with a -elimination activity that 
incises the phosphate backbone 3’ of the abasic site. Structurally the DNA glycosylases 
consist of five superfamilies (reviewed in Dalhus et al 2009 FEMS). The helix-hairpin-helix 
(HhH) and the helix-two-turn-helix (H2TH) family are termed after their distinctive DNA-
binding motifs. The human 8-oxoguanine (8-oxoG) DNA glycosylase, Ogg1, and human 
EndonucleaseIII, Nth1, belong to the HhH family (Bjørås et al, EMBO, 1997; PNAS; 
Aspinwall et al, PNAS, 1997), whereas Neil1, 2 and 3 belong to the H2TH. Nth1 and Neil1, 2 
and 3 display overlapping substrate affinities removing a broad range of oxidative base 
lesions, including formamidopyrimidines, 5-hydroxypyrimidines and hydantoins (Hazra et al, 
JBC 2002, Hazra et al, PNAS, 2002; Morland et al, NAR 2002; Liu M, PNAS, 2010). The 
third and the fourth classes of DNA glycosylases are the uracil DNA glycosylase (Ung) and 
the alkyladenine DNA glycosylase (Aag). In addition to alkylated bases the Aag family 
removes deaminated purines (hypoxanthine and xanthine) and ethenoadducts such as 
ethenoadenine.   
In this report we analyzed the effect of FAA and SA on the activity of four human 
DNA glycosylases (Ogg1, Neil1, Neil2 and Ung2). FAA inhibited all DNA glycosylases 
removing oxidative base lesions, suggesting that inhibition of BER of mutagenic base lesions 
play a significant role for development of cancer and somatic mosaicism in liver of HT1 
patients.
Materials and methods 
Enzyme purification 
 
Human Ogg1 was expressed and purified as previously described  (Dalhus et al. 2011). 
Purified recombinant human Ung2 , containing the core catalytic domain (lacking 84 amino 
acids at the N-terminal), was a kind gift from Professor Geir Slupphaug. Plasmids for 
purification of Neil1  (pET22 Neil1) and Neil2 (pET22Neil2) were a kind gift from Professor 
Sankar Mitra. BL21 Codon Plus RIL cells (Stratagene) containing plasmids of Neil1 and 
Neil2  were grown in LB-medium supplemented with sorbitol (0.5 M), betain (2.5 mM). 
Protein expression was induced when the cell density reached an OD600 of 1.0 by adding 1mM 
IPTG. Induced cells were grown for 2 (Neil 1) and 4 hr (Neil 2) prior to harvesting by 
centrifugation. Cell pellets were resuspended in 300 mM NaCl, 50 mM Na2HPO4/NaH2PO4 
(pH 8.0) and 10 mM 2-mercaptoethanol (2-ME) (buffer A). Crude extracts were prepared by 
sonication, and the extracts were applied to nickel NTA-agarose columns pre-equilibrated 
with buffer A. Unbound proteins were removed by extensive washing with buffer A 
supplemented with 50 mM imidazole. The proteins were eluted with 300 mM imidazole in 
buffer A. Fractions containing Neil1 or Neli2 were pooled and dialyzed against 50 mM NaCl, 
10 mM MES (pH 6.0) and 10 mM 2-ME (buffer B), and applied on a Hitrap SP column (GE 
Lifesciences). The proteins were eluted with a salt gradient to 2 M NaCl in buffer B. Protein 
fractions were identified by SDS-PAGE gel, pooled, and concentrated. Protein solutions for 
assays were supplemented with 20 % glycerol prior to storage at -70°C (Neil1) and -20°C 
(Neil2). 
 
DNA glycosylase  activity assay 
 
The DNA glycosylase assays were performed in a reaction buffer of 50 mM MOPS,  pH 7.5, 
1mM ethylenediaminetetraacetic acid, 5 %  glycerol, 1mM dithiothreitol with 10 fmol 32P 
end-labeled duplex oligonucleotide substrate and enzyme as indicated in a total volume of 10 
μl at 37°C for 30 min. Increasing concentrations of the metabolites FAA or SA were added to 
the reaction mixtures as indicated. The DNA glycosylase assay was terminated by addition of 
NaOH to a final concentration of 0.1 M, incubated for 20 min at 70°C and neutralized with 
HCl. The reaction products were separated on a 20 % PAGE and quantified by phosphor 
imaging (Typhoon™, software: Image Quant TL Version 2003.02 Amersham Biosciences).  
 
DNA substrates 
  
The single stranded oligonucleotides were 32P-end labeled at the 5-end using T4 
polynucleotide kinase (MBI Fermantas) and [32P]ATP (GE Healthcare). The following 
DNA-strands were used substrates containing 8-oxoG, 5-hydroxycytosine (5-ohC) and uracil 
(U): 5’- GGCGGCATGACCC[8-oxoG]GAGGCCCATC-3’; 5’ GCATGCCTGCACGG [5-
ohdC] CATGGCCAGATCCCCGGGTACCGAG-3’; 5-GCTCATGCGCAG [ U ] 
CAGCCGTACTCG-3’. The oligonucleotides were hybridized to their complementary strands 
to generate the double-stranded substrates 8-oxoG:C, 5-ohC:G and U:A, respectively. The 
32P-labeled DNA substrates were then purified on a 20 % native polyacrylamide gel, the 
radiolabeled bands were excised from the gel, eluted in H2O and stored at 4°C. 
 
Others 
 
FAA was produced as previously described (RAVDIN and CRANDALL 1951) and stored at -
70°C. SA was ordred from Sigma Aldricht, eluted in H2O and stored at  -20°C. Bradford 
protein assay (Bio-Rad) was used to measure protein concentration. 
 
Statistics 
  
A nonparametric test (Passing & Bablok) and Spearman's rank correlation were used in 
regression analyses (Excel Analyse-it, v2.21).  
 
 
Results
DNA glycosylase activity was assayed on duplex oligonucleotides containing one single base 
lesion at a defined position in the sequence. An 8-oxoG containing oligo substrate was used to 
monitor Ogg1 activity, whereas 5-ohC was used to monitor Neil1 and Neil2 activity. Ung2 
activity was monitored using an oligoe containing uracil. The DNA glycosylase activities was 
analyzed by denaturing polyacrylamide gelelectrophoreses as exemplified in Fig. 2a. The 
intensity of the cleaved substrate (8-oxoG) band is fading with increasing concentrations of 
FAA, demonstrating that the DNA glycosylase (Ogg1) is inhibited by FAA. Figures 2b-d 
summarize DNA glycosylase assays with Ogg1, Neil1 and Neil2, respectively. The diagrams 
in figures 2b- d show an initial upper platau (“A”), an apparently linear falling segment and a 
final lower plateau (“B”). The intensity of the product bands, read as light intensity (LI) of the 
storage phosphor screen, was normalized to the positive control (the sample without the actual 
test substance, [C] = 0) for each electrophoresis gel; and then plotted against increasing [C].  
Each column shows the mean value of the replicates with 95%-CI . To evaluate the observed 
descending part of the curve and to calculate [C50] that corresponds to 50% inhibition, A and 
B were calculated as the median levels from all gels of the initial plateau and final plateau, 
respectively. The LI values from the intervening concentrations were used in a non-parametric 
regression (Passing & Bablok)  LIi = a + b·log[C]i + i; i = 1,…n. The estimated regression 
coefficients â and  are presented with 95% confidence intervals together with Spearman’s 
correlation coefficient. From the estimated coefficients the [C50] that corresponds to 50% 
inhibition was calculated: (A-B)/2 = â + ·log[C50]. The plateaus “A” and “B” were 
calculated for each gel as the mean value of the positive and negative control respectively and 
the samples visually judged at approximately the same level. In sum, the results presented in 
figures 2b-d showed strong inhibition of Ogg1, Neil1 and Neil2 activity, respectively, with 
increasing FAA-concentrations. The [C50] values for inhibition of Ogg1, Neil1 and Neil2 by 
FAA were calculated to, 1000, 6, and 32 nM, respectively. In contrast, FAA showed no 
significant inhibition of uracil removal by Ung2 (data not shown).  Next, DNA glycosylase 
assays with increasing concentrations of SA showed no inhibition of Neil1, Neil2, Ogg1 and 
Ung2 (data not shown). It thus appears that FAA exhibit a strong inhibitory effect on DNA 
glycosylases removing a broad range of mutagenic DNA base lesions, suggesting an 
important mechanism for cancer development and somatic mosaicms in liver of HT1 patients.  
bˆ
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Discussion
Oxidative DNA modifications are potent premutagenic lesions formed spontaneously at high 
frequencies in the genomes of aerobic organisms and BER is the major DNA repair pathway 
that corrects oxidative base damage. In human cells, BER of oxidative base lesions is initiated 
by at least seven different DNA glycosylases, which have redundant activity. In this report we 
demonstrated that FAA strongly inhibit three different human DNA glycosylases (Neil1, 
Neil2 and Ogg1) removing numerous oxidative base lesions. In contrast, FAA showed no 
effect on the human Ung2 glycosylase, which remove uracil in DNA. Moreover, SA shows no 
inhibition of any of the DNA glycosylases examined. These data indicate that impairment of 
DNA glycosylases initiating BER of oxidative lesions by FAA increase mutagenesis and, 
consequently, lead to cancer development in HT1 patients. 
One of the most common mutagenic adducts that result from oxidative DNA damage 
is 8-oxoG (Shibutani, Takeshita, and Grollman 1991) Ogg1 is the major DNA glycosylase for 
removal of 8-oxoG opposite C and Neil1 function as a backup activity  (Bjoras et al. 
1997;Morland et al. 2002). Further, Neil1 and Neil2 remove oxidized pyrmimidins, including 
5ohC, 5ohU and di-hT, which are mutagenic lesions(Feig, Sowers, and Loeb 1994). 
Consequently, we suggest that inhibition of Ogg1, Neil1 and Neil2 by FAA in liver cells of 
HT1 patients increase mutagenesis.      
Numerous DNA glycosylase deficient mouse models have been developed to 
investigate the impact of endogenous genotoxic stress for cancer development and other 
diseases. Single mutants with deficiencies in DNA glycosylases removing oxidative base 
lesions such as neil1-/-, ogg1-/-, nth1-/- or myh-/- showed no or modest increase in cancer 
development(Chan et al. 2009;Xie et al. 2004), However, tumor formation increased several 
fold in the double mutants neil1-/- nth1-/- and ogg1-/- myh-/- demonstrating that redundancy in 
repair of endogenous oxidative DNA base damage is important to prevent tumor formation.   
By example, Ogg1 Myh deficient mice started to develop tumors at the age of two months 
(Xie et al. 2004). In this work we showed that FAA strongly inhibited DNA glycosylases 
excising oxidative damage, suggesting that reduced capacity to initiate BER results in 
accumulation of oxidative DNA base damage and increased mutagenesis in HT1 patients. In 
addition endogenous oxidative stress is elevated in hepatocytes of HT1 patients (Jorquera and 
Tanguay 1997), supporting that increased accumulation of oxidative DNA base lesions, 
impaired repair and increased mutagenesis is a major cause of hepatocellular carcinoma and 
somatic mosaicms in liver. 
Dyk at al used a comet assay to examine if BER was inhibited in cells treated with SA 
or p-hydroxyphenylpyruvate (van Dyk et al. 2010). However, it is unclear from this work 
whether DNA glycosylase activities are affected by SA or p-hydroxyphenylpyruvate. In a 
recent paper, Dyk showed reduced gene expression of Ogg1 in lymphocytes from two HT1 
patients (van Dyk and Pretorius 2012) indicating that down-regulation of DNA glycosylases 
at the transcriptional level could impair BER of oxidative damage.  
In sum, our data demonstrate that FAA is a very efficient inhibitor of DNA 
glycosylases removing a broad range of mutagenic base lesions, suggesting an important 
contribution to the pathogenesis of HT1.  
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Figure Legends 
 
Fig. 1 (a) Pathway of tyrosin degradation. Tyrosinaemia type I (HT1) is an enzyme deficiency 
of the last step of tyrosine degradation. Blockage of fumarylacetoacetate hydrolase (FAH) 
leads to accumulation of fumarylacetoacetate (FAA) and maleylacetoacetate which are 
converted to succinylacetoacetate and succinylacetone. (b) The Base Excision Repair (BER) 
pathway. BER is initiated by a DNA glycosylase which identifies a base lesion (I) and creates 
an abasic site (II). The abasic site is removed by phosphodiesterases/AP-lyases, and repair is 
completed by DNA polymerase and DNA ligase (III).  
.  
Fig. 2 (a) DNA glycosylase assay with 8-oxoG:C duplex DNA and human Ogg1. 10 fmol 5’ 
end-labeled 8oxoG:C duplex DNA was incubated with 1.6 fmol human Ogg1. Substrate and 
product of the DNA glycosylase reaction was separated on a denaturing polyacrylamide gel 
and visualized by Image Quant. Lane 1: Positive control with Ogg1 and without FAA. Lane 2 
-8: Samples with Ogg1 and increasing concentrations of FAA (10-1-105 nM). Lane 9: 
Negative control (without Ogg1). The Ogg1 activity decreased with increasing concentrations 
of FAA. (b) 8-oxoG:C activity was measured with 1.6 fmol human Ogg1for seven different 
concentrations of FAA as indicated with eight replicates. The columns show the mean value 
of 8 replicates with 95%-CI. The total number of samples including controls was 80. 23 
samples in the descending area of the curve were used in the regression analyses with the 
following results: a= 1,21 (CI: 1,03 – 1,48 ),  b= -0,12 (CI: -0,21 – 0,06 ).  Spearman 
correlation coefficient: -0,69 (CI: -0,86 – -0,39). 2-tailed p (t-approximation, corrected for 
ties): 0,0002. LOG [C50]: 2,99. (c) DNA glycosylase assay with 5-ohC:G duplex DNA and 
human Neil1. 10 fmol 5’ end-labeled 5-ohC:G duplex DNA was incubated with 20 fmol 
human Neil1 and increasing concentrations FAA.  Enzyme activity was measured for seven 
different concentrations of FAA as indicated with 8 replicates. The columns show the mean 
value of the replicates with 95%-CI. The total number of samples including controls was 72. 
33 samples in the descending area of the curve were used in the regression analyses with the 
following results: a= 0,93 (CI: 0,86 – 1,00 ),  b= -0,08 (CI: -0,12 – 0,05 ).  Spearman 
correlation coefficient: -0,51 (CI: -0,72 – -0,20). 2-tailed p (t-approximation, corrected for 
ties): 0,0027. LOG [C50]: 0,79. (d) DNA glycosylase assay with 5-ohC:G duplex DNA and 
human Neil2. 10 fmol 5’ end-labeled 5-ohC:G duplex DNA was incubated with 400 fmol 
human Neil2 and increasing concentrations FAA. Enzyme activity was measured for seven 
different concentrations of FAA as indicated with 8 replicates. The columns show the mean 
value of the replicates with 95%-CI. The total number of samples including controls was 72. 2 
samples were excluded for technical reasons. 43 samples in the descending area of the curve 
were used in the regression analyses with the following results: a= 0,99 (CI: 0,91 – 1,07 ),  b= 
-0,11 (CI: -0,16 – 0,08 ).  Spearman correlation coefficient: -0,56 (CI: -0,74 – -0,31). 2-tailed 
p (t-approximation, corrected for ties): < 0,0001. LOG [C50]: 1,51. 
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